

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 14 January 2002 (14.01.02)	
International application No. PCT/DK01/00356	Applicant's or agent's file reference 10028-WO
International filing date (day/month/year) 23 May 2001 (23.05.01)	Priority date (day/month/year) 24 May 2000 (24.05.00)
Applicant RASMUSSEN, Michael, Dolberg	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 29 November 2001 (29.11.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Frédéric VIGNE Telephone No.: (41-22) 338.83.38
--	---

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 14 January 2002 (14.01.02)	
International application No. PCT/DK01/00356	Applicant's or agent's file reference 10028-WO
International filing date (day/month/year) 23 May 2001 (23.05.01)	Priority date (day/month/year) 24 May 2000 (24.05.00)
Applicant RASMUSSEN, Michael, Dolberg	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
29 November 2001 (29.11.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Frédéric VIGNE Telephone No.: (41-22) 338.83.38
---	--

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

REC'D 03 SEP 2002

WIPO

PCT

To:

The International Bureau of WIPO
34, chemin des Colombettes
CH - 1211 Geneva 20
Switzerland

PCT

NOTIFICATION CONCERNING
DOCUMENTS TRANSMITTED

Date of mailing
(day/month/year)

30.08.2002

International application No: PCT/DK01/00358

This International Preliminary Examining Authority transmits herewith the following documents:

1. ☐ demand (Rule 61.1(a)).
2. ☒ copy of the international preliminary examination report and its annexes (Rule 71.1).
3. ☐ _____ other documents (*specify*):

Name und mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Conner, M


Tel. +49 89 2399-2241



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 10028.204-wo		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/DK01/00356	International filing date (day/month/year) 23/05/2001	Priority date (day/month/year) 24/05/2000	
International Patent Classification (IPC) or national classification and IPC C12N15/90			
Applicant NOVOZYMES A/S & al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application 			
Date of submission of the demand 29/11/2001		Date of completion of this report 27.08.2002	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Trommsdorff, M Telephone No. +49 89 2399 7361	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK01/00356

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-47 as originally filed

Claims, No.:

1-61 as originally filed

Sequence listing part of the description, pages:

1-8, filed with the demand

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK01/00356

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	20, 26, 57
	No:	Claims	1-19, 21-25, 27-56, 58-61
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-61
Industrial applicability (IA)	Yes:	Claims	1-61
	No:	Claims	

2. Citations and explanations
see separate sheet

1. Cited documents

D1: US-A-5435730

D2: EP-A2-0965641

D3: WO-A2-0009705

2. Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 2.1. Claim 1 is directed to a method wherein a gene of interest is introduced into a host cell, integrated into the chromosome of said cell and amplified.

D1 discloses recombinant DNA molecules comprising the *Streptomyces gal* operon (the *galE*, *galT*, *galK* genes and their promoters) or parts of it. D1 further teaches the use of the *gal* operon as a selection marker in a host mutant which contains a nonfunctional *gal* operon: a recombinant DNA molecule comprising the *gal* operon and a gene of interest can be transformed into a host cell and integrated by homologous recombination. This method allows the expression of a gene of interest without the need of an antibiotic selection (col.7, l.7-51).

Even though D1 does not mention the use of the *gal* operon for the amplification of the gene of interest, it appears that the disclosed recombinant molecules would be suitable for the claimed method. Hence, D1 is prejudicial to the novelty of claims 1-10, 15-19, 32-36, 44-50, 52-56 and 59 (Art. 33(2) PCT).

- 2.2. D2 describes how a promoterless foreign gene can be inserted into the *lac* operon of *S. thermophilus*, transformed into *S. thermophilus*, integrated into the host genome and expressed. The erythromycin resistance gene used to select integration events is released by a second recombination event, resulting in a perfect replacement of the *lac* operon and a stable expression of the gene of interest (example 1 and claims).

Thus, D2 is novelty destroying to the subject-matter of claims 2, 4, 16-19, 21-25, 27-32, 38-46, 55, 56, 58-61 (Art. 33(2) PCT).

- 2.3. D3, cited in the application, teaches the use of *galE* for selection of transformants

on a medium containing galactose (p.43, l.25- p.46, l.28) and gives several examples of transformed plants which have stably integrated the gene of interest. Hence, in D3 the same transformation method as in the application is used which has the advantage of circumventing the need for antibiotic selection.

Thus, D3 is novelty destroying to the subject-matter of claims 2, 5-15, 17, 24, 25, 30-37, 41, 44, 45, 47-54, 59 and 60 (Art. 33(2) PCT).

- 2.4. The remaining dependent claims, if novel, do not appear to recite any technical features that would justify an inventive step (Art. 33(3) PCT).
- 2.5. The subject-matter of claims 1-61 is industrially applicable in the field of microbiology (Art. 33(4) PCT).
- 2.6. Hence, the idea of using the gal operon as a selection marker in order to avoid the need for antibiotics was known in the art and even though none of the cited prior art documents mentions its use for gene amplification, the described systems appear to be suitable for gene amplification and thus prejudicial to the novelty of the claims as formulated. Indeed, the claimed expression systems do not contain any technical features that could differentiate them from the prior art. Moreover, the claims do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined: the description only gives the example of the galE operon, whereas the claims vaguely claim any "amplification unit". This vague term does not enable the skilled person to determine which technical features are necessary to perform the stated function, i.e. the amplification of the gene of interest.
- 2.7. Although claims 1 and 3 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness. Moreover, lack of clarity of the claims as a whole arises, since the plurality of independent claims makes it difficult, if not impossible, to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection.

Hence, the claims do not meet the requirements of Article 6 PCT.

In order to overcome this objection, it would appear appropriate to file an amended set of claims defining the relevant subject-matter in terms of a minimum number of independent claims in each category followed by dependent claims covering features which are merely optional (Rule 6.4 PCT).

- 2.8. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 and D2 is not mentioned in the description, nor are these documents identified therein.

AMENDED CLAIMS

1. A sensor membrane comprising at least one polymer material, at least one surfactant and at least one hydrophilic compound, which is not a polymer, in admixture.
- 5 21. A method for the preparation of a sensor membrane comprising the steps of:
 - mixing at least one polymer material, at least one surfactant, at least one hydrophilic compound, which is not a polymer, and at least one solvent
 - 10 - applying said mixture onto a substrate
 - solvent evaporation, and
 - optionally membrane conditioning

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 01/00356

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/90, C12N 15/75, C12N 15/61, C12N 15/54
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5435730 A (CRAIG W. ADAMS ET AL), 25 July 1995 (25.07.95), column 7, line 8 - line 51 --	1-61
X	EP 0965641 A2 (SOCIETE DES PRODUITS NESTLE S.A.), 22 December 1999 (22.12.99), whole document, specially example 1 and the claims --	1-4,16-32, 38-46,55-61
A	--	5-15,33-37, 47-54
X	WO 0009705 A2 (DANISCO A/S), 24 February 2000 (24.02.00), page 37, line 3 - line 16; page 39, line 8 - line 19; page 40, line 11 - line 14, the claims -- -----	1-61

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 July 2001

Date of mailing of the international search report

02-08-2001

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson/BS
Telephone No. +46 8 782 25 00

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number
WO 01/90393 A1

(51) International Patent Classification⁷: C12N 15/90,
15/75, 15/61, 15/54

(21) International Application Number: PCT/DK01/00356

(22) International Filing Date: 23 May 2001 (23.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 00824 24 May 2000 (24.05.2000) DK
60/208,052 30 May 2000 (30.05.2000) US

(71) Applicant (for all designated States except US):
NOVOZYMES A/S [DK/DK]; Krogshøjvej 36, DK-2880
Bagsværd (DK).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RASMUSSEN,
Michael, Dolberg [DK/DK]; Syvbjergvej 151, DK-2625
Vallensbæk (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/90393 A1

(54) Title: METHOD FOR INCREASING GENE COPY NUMBER IN A HOST CELL AND RESULTING HOST CELL

(57) Abstract: The invention relates to a method for increasing the copy number of a chromosomally integrated expression cassette in a microbial strain without leaving antibiotic resistance markers behind in the strain, the necessary genetic constructs, and the strains resulting from the method of the invention. In the method an expression cassette comprising a gene of interest and a copy of a gene being non-functional in the chromosome of the host cell is introduced in the host cell. The host cell is cultivated in the presence of a precursor to an inhibiting compound produced if the expression cassette is not integrated into the chromosome.

Method for Increasing Gene Copy Number in a host cell and resulting host cell

Field of the Invention

5 The invention relates to a method for increasing the copy number of a chromosomally integrated expression cassette in a microbial strain without leaving antibiotic resistance markers behind in the strain, the necessary genetic constructs, and the strains used in and resulting from the method of the invention.

10 It is desirable for the biotech industry to provide microbial strains devoid of antibiotic resistance markers comprising several chromosomally integrated copies of a gene of interest, for the industrial high yield production of polypeptides.

15 Background of the Invention

 The present debate concerning the industrial use of recombinant DNA technology has raised some questions and concern about the use of antibiotic marker genes. An antibiotic marker gene is traditionally used as a means to select for

20 strains carrying multiple copies of both the marker gene and an accompanying expression cassette coding for a polypeptide of industrial interest. Amplification of the expression cassette by increasing the copy number in a microbiological production strain is desirable because there is very often a direct

25 correlation between the number of copies and the final product yields. The amplification method using antibiotic selection has been used extensively in many host strains over the past 15 years and has proven to be a very efficient way to develop high yielding production strains in a relatively short time,

30 irrespective of the expression level of the individual expression cassettes.

 In order to comply with the current demand for recombinant production host strains devoid of antibiotic markers, we have looked for possible alternatives to the present technology that

will allow substitution of the antibiotic markers we use today with new marker genes.

The catabolic pathway of galactose in bacilli is very similar to the pathway of other sugars. The carbon molecule is transported into the cell via a permease, a kinase charges the molecule with a phosphate group and a transferase reaction transfers the phosphate group to a glucose molecule which is then shuttled directly into the glycolytic pathway. In the case of galactose catabolism the transferase reaction generates UDP-galactose as a sideproduct which is a very toxic compound for all living cells. This compound is normally converted to UDP-glucose by an epimerase coded for by the *galE* gene. The use of *galE* in a simple selection method for plasmid transformed cells, especially plant cells, is mentioned in WO 00/09705.

15

Summary of the Invention

The problem to be solved by the present invention is to increase the copy number of a chromosomally integrated expression cassette in a microbial strain in a way by which a resulting host cell devoid of antibiotic markers is provided for the use in industrial production of polypeptides in high yields.

The solution is based on that the present inventors demonstrated that a nucleotide construct comprising an amplification unit as defined herein can integrate into the chromosome of a host cell and increase in number of chromosomally integrated copies without the use of classical antibiotic markers or antibiotics.

Accordingly, in a first aspect the invention relates to a method for increasing the number of copies of an amplification unit integrated into a host cell chromosome, wherein the method comprises the steps of:

- a) rendering a chromosomal gene of a host cell non-functional, wherein the host cell becomes susceptible to an inhibitory compound endogenously produced by the host cell

35

when the host cell is cultivated in a medium comprising a precursor;

- b) making a nucleic acid construct comprising an amplification unit, wherein the unit comprises:
 - 5 i) an expression cassette comprising at least one copy of a gene of interest; and
 - ii) an expressible copy of the chromosomal gene of step a), wherein the unit integrates into the host cell chromosome;
- 10 c) introducing the nucleic acid construct of step b) into the host cell of step a), wherein at least one copy of the amplification unit integrates into the host cell chromosome;
- d) cultivating the host cell of step c) in a medium
- 15 comprising the precursor, wherein a chromosomally integrated copy of the amplification unit is duplicated or multiplied on the host cell chromosome;
- e) selecting a host cell comprising two or more chromosomally integrated copies of the amplification unit; and optionally
- 20 f) performing one or more cycles of steps d) and e) using the host cell selected in step e) in each new cycle; wherein the number of chromosomally integrated copies of the amplification unit increases with each repeat.

Further, in a second aspect the invention relates to a
25 method for constructing a host cell comprising at least one copy of an amplification unit integrated into the host cell chromosome, wherein the method comprises the steps of:

- a) rendering a chromosomal gene of a host cell non-functional, wherein the host cell becomes susceptible to an
- 30 inhibitory compound endogenously produced by the host cell when the host cell is cultivated in a medium comprising a precursor;
- b) making a nucleic acid construct comprising an amplification unit, wherein the unit comprises:
 - 35 i) an expression cassette comprising at least one copy of a gene of interest; and

- ii) an expressable copy of the chromosomal gene of step a), wherein the unit integrates into the host cell chromosome;
- c) introducing the nucleic acid construct of step b) into the host cell of step a) and cultivating the host cell in a medium comprising the precursor, wherein at least one copy of the amplification unit integrates into the host cell chromosome; and
- d) selecting a host cell comprising at least one chromosomally integrated copy of the amplification unit.

A third aspect of the invention relates to a method for increasing the number of copies of an amplification unit integrated into a host cell chromosome, wherein the method comprises the steps of:

- a) providing a host cell, wherein a chromosomal gene has been rendered non-functional, whereby the host cell becomes susceptible to an inhibitory compound endogenously produced by the host cell when the host cell is cultivated in a medium comprising a precursor;
- b) introducing a nucleic acid construct into the host cell of step a), the nucleic acid construct comprising an amplification unit, wherein the unit comprises:
 - i) an expression cassette comprising at least one copy of a gene of interest; and
 - ii) an expressable copy of the chromosomal gene of step a), wherein at least one copy of the amplification unit integrates into the host cell chromosome;
- c) cultivating the host cell of step b) in a medium comprising the precursor, wherein a chromosomally integrated copy of the amplification unit is duplicated or multiplied on the host cell chromosome;
- d) selecting a host cell comprising two or more chromosomally integrated copies of the amplification unit; and optionally
- e) performing one or more cycles of steps c) and d) using the host cell selected in step d) in each new cycle; wherein the

number of chromosomally integrated copies of the amplification unit increases with each cycle.

As clear from above, genetic tools are provided for performing the method of the invention as described herein.

5 Accordingly in a fourth aspect the invention relates to an amplification unit comprising:

- a) an expression cassette comprising at least one copy of a gene of interest; and
- b) an expressable copy of a conditionally essential chromosomal
10 gene of a host cell; wherein the unit integrates into the host cell chromosome upon introduction of the nucleic acid construct into the host cell.

Further in a fifth aspect the invention relates to a nucleic acid construct comprising a unit as defined in any of
15 the previous aspects.

The method of the invention achieves the construction of a host cell comprising at least one chromosomally integrated copy of the amplification unit as defined above, where such a host cell is highly desirable for industrial production of
20 polypeptides in high yields.

Consequently in a sixth aspect the invention relates to a host cell wherein a chromosomal gene has been rendered non-functional leaving the host cell susceptible to an inhibitory compound endogenously produced by the host cell when cultivated
25 in a medium comprising a precursor; and wherein the host cell comprises an amplification unit as defined in any of the previous aspects or a nucleotide construct as defined in the previous aspect.

In a final aspect the invention relates to a process for
30 producing a polypeptide of interest, wherein the process comprises a step of cultivating a host cell as defined in the previous aspect.

Drawings

35 Figure 1: Shows a Southern blot which demonstrated hybridization to flanking fragments of the dal locus and a

strong hybridization band to the expression cassette corresponding to the size of the plasmid pMOL1807 (SEQ ID 2) in a non-limiting example herein.

5 Definitions

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g.,
10 Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989") *DNA Cloning: A Practical Approach*, Volumes I and II /D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait
15 ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds (1985)); *Transcription And Translation* (B.D. Hames & S.J. Higgins, eds. (1984)); *Animal Cell Culture* (R.I. Freshney, ed. (1986)); *Immobilized Cells And Enzymes* (IRL Press, (1986)); B. Perbal, *A Practical Guide To Molecular*
20 *Cloning* (1984).

A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or
25 prepared from a combination of natural and synthetic molecules.

A "nucleic acid molecule" or "nucleotide sequence" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine,
30 deoxythymidine, or deoxycytidine; "DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of
35 the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term includes double-stranded

DNA found, inter alia, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

10 A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see 15 Sambrook et al., supra). The conditions of temperature and ionic strength determine the "stringency" of the hybridization.

A DNA "coding sequence" or an "open reading frame (ORF)" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo 20 when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA 25 from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

30 An expression vector is a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and terminator sequences, and optionally one or more 35 origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression

vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide" that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

A chromosomal gene is rendered non-functional if the polypeptide that the gene encodes can no longer be expressed in a functional form. Such non-functionality of a gene can be induced by a wide variety of genetic manipulations as known in the art, some of which are described in Sambrook et al. vide supra. Partial deletions within the ORF of a gene will often render the gene non-functional, as will mutations.

The term "an expressable copy of a chromosomal gene" is used herein as meaning a copy of the ORF of a chromosomal gene, wherein the ORF can be expressed to produce a fully functional gene product. The expressable copy may not be transcribed from the native promoter of the chromosomal gene, it may instead be transcribed from a foreign or heterologous promoter, or it may indeed be promoterless and expressed only by transcriptional read-through from a gene present upstream of the 5' end of the ORF. Transcriptional read-through is intended to have the same meaning here as the generally recognized meaning in the art.

"Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding
5 segment to the terminator.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein
10 encoded by the coding sequence.

"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

As used herein the term "nucleic acid construct" is
15 intended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is intended to indicate a nucleic acid segment which may be single- or double-stranded, and which may be based on a complete or partial naturally occurring nucleotide sequence
20 encoding a polypeptide of interest. The construct may optionally contain other nucleic acid segments.

The nucleic acid construct of the invention encoding the polypeptide of the invention may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA
25 library and screening for DNA sequences coding for all or part of the polypeptide by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., supra).

The nucleic acid construct of the invention encoding the
30 polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phosphoramidite method,
35 oligonucleotides are synthesized, e.g. in an automatic DNA

synthesizer, purified, annealed, ligated and cloned in suitable vectors.

Furthermore, the nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed
5 genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid construct, in accordance with standard techniques. The nucleic acid construct may also be prepared by polymerase chain
10 reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491.

The term nucleic acid construct may be synonymous with the term "expression cassette" when the nucleic acid construct contains the control sequences necessary for expression of a
15 coding sequence of the present invention

The term "control sequences" is defined herein to include all components which are necessary or advantageous for expression of the coding sequence of the nucleic acid sequence. Each control sequence may be native or foreign to the nucleic
20 acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and
25 translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.

The control sequence may be an appropriate promoter sequence, a
30 nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control sequences which mediate the expression of the polypeptide. The promoter may be
35 any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be obtained from genes

encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to
5 terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a polyadenylation sequence, a
10 sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in
15 the present invention.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the expressed polypeptide into the cell's secretory pathway of the
20 host cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence
25 may contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted polypeptide. A foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign
30 signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the [enzyme] relative to the natural signal peptide coding region normally associated with the coding sequence. The signal peptide coding region may be obtained
35 from a glucoamylase or an amylase gene from an *Aspergillus* species, a lipase or proteinase gene from a *Rhizomucor* species,

the gene for the alpha-factor from *Saccharomyces cerevisiae*, an amylase or a protease gene from a *Bacillus* species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), the *Bacillus subtilis* neutral protease gene (*nprT*), the *Saccharomyces cerevisiae* alpha-factor gene, or the *Myceliophthora thermophilum* laccase gene (WO 95/33836).

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator systems. In yeast, the *ADH2* system or *GAL1* system may be used. In filamentous fungi, the *TAKA* alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and the *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the

polypeptide would be placed in tandem with the regulatory sequence.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli* lac operon, the *Streptomyces coelicolor* agarase gene (dagA), the *Bacillus subtilis* levansucrase gene (sacB), the *Bacillus subtilis* alkaline protease gene, the *Bacillus licheniformis* alpha-amylase gene (amyL), the *Bacillus stearothermophilus* maltogenic amylase gene (amyM), the *Bacillus amyloliquefaciens* alpha-amylase gene (amyQ), the *Bacillus amyloliquefaciens* BAN AMYLASE GENE, the *Bacillus licheniformis* penicillinase gene (penP), the *Bacillus subtilis* xylA and xylB genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80:21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (glaA), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium oxysporum* trypsin-like protease (as described in U.S. Patent No. 4,288,627, which is incorporated herein by reference), and hybrids thereof. Particularly preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus*

niger neutral α -amylase and *Aspergillus oryzae* triose phosphate isomerase), and *glaA* promoters. Further suitable promoters for use in filamentous fungus host cells are the ADH3 promoter (McKnight et al., The EMBO J. 4 (1985), 2093 - 2099) or the
5 *tpiA* promoter.

Preferred terminators for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* α -glucosidase, and
10 *Fusarium oxysporum* trypsin-like protease. for fungal hosts) the TPI1 (Alber and Kawasaki, op. cit.) or ADH3 (McKnight et al., op. cit.) terminators.

Preferred terminators for yeast host cells are obtained from the genes encoding *Saccharomyces cerevisiae* enolase,
15 *Saccharomyces cerevisiae* cytochrome C (*CYC1*), or *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.

An effective signal peptide coding region for bacterial
20 host cells is the signal peptide coding region obtained from the maltogenic amylase gene from *Bacillus* NCIB 11837, the *Bacillus stearothermophilus* α -amylase gene, the *Bacillus licheniformis* subtilisin gene, the *Bacillus licheniformis* β -lactamase gene, the *Bacillus stearothermophilus* neutral
25 proteases genes (*nprT*, *nprS*, *nprM*), and the *Bacillus subtilis* *PrsA* gene. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57:109-137.

An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained
30 from *Aspergillus oryzae* TAKA amylase gene, *Aspergillus niger* neutral amylase gene, the *Rhizomucor miehei* aspartic proteinase gene, the *Humicola lanuginosa* cellulase or lipase gene, or the *Rhizomucor miehei* lipase or protease gene, *Aspergillus* sp. amylase or glucoamylase, a gene encoding a *Rhizomucor miehei*
35 lipase or protease. The signal peptide is preferably derived from a gene encoding *A. oryzae* TAKA amylase, *A. niger* neutral

a-amylase, *A. niger* acid-stable amylase, or *A. niger* glucoamylase.

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids

which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

A conditionally essential gene may function as a selectable marker. Examples of bacterial conditionally essential selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, that are only essential when the bacterium is cultivated in the presence of D-alanine; or the genes encoding enzymes involved in the removal of UDP-galactose from the bacterial cell when the cell is grown in the presence of galactose. Non-limiting examples of such genes are those from *B. subtilis* or *B. licheniformis* encoding UTP-dependent phosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or UDP-galactose epimerase (EC 5.1.3.2).

Antibiotic selectable markers confer antibiotic resistance to such antibiotics as ampicillin, kanamycin, chloramphenicol, tetracycline, neomycin, hygromycin or methotrexate. Suitable markers for yeast host cells are *ADE2*, *HIS3*, *LEU2*, *LYS2*, *MET3*, *TRP1*, and *URA3*. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sc* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species. Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* markers of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* marker of *Streptomyces hygroscopicus*. Furthermore, selection may be

accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector, or of
5 a smaller part of the vector, into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

The vectors, or smaller parts of the vectors such as amplification units of the present invention, may be integrated
10 into the host cell genome when introduced into a host cell. For chromosomal integration, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination.

15 Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the
20 chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous
25 with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic
30 acid sequences.

On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and,
35 furthermore, may be non-encoding or encoding sequences. The copy number of a vector, an expression cassette, an

amplification unit, a gene or indeed any defined nucleotide sequence is the number of identical copies that are present in a host cell at any time. A gene or another defined chromosomal nucleotide sequence may be present in one, two, or more copies on the chromosome. An autonomously replicating vector may be present in one, or several hundred copies per host cell.

An amplification unit of the invention is a nucleotide sequence that can integrate into the chromosome of a host cell, whereupon it can increase in number of chromosomally integrated copies by duplication or multiplication. The unit comprises an expression cassette as defined herein comprising at least one copy of a gene of interest and an expressible copy of a chromosomal gene, as defined herein, of the host cell.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAM β 1. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75:1433).

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due to mutations that occur during replication.

The cell is preferably transformed with a vector comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome. "Transformation" means introducing a vector comprising a

nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid
5 sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.

The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The
10 host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a Bacillus cell, e.g., Bacillus alkalophilus, Bacillus
15 amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus coagulans, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis; or a Streptomyces cell, e.g., Streptomyces
20 lividans or Streptomyces murinus, or gram negative bacteria such as E. coli and Pseudomonas sp. In a preferred embodiment, the bacterial host cell is a Bacillus lentus, Bacillus licheniformis, Bacillus stearothermophilus or Bacillus subtilis cell.

25 The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-
30 Abelson, 1971, Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278).

The host cell may be a fungal cell. "Fungi" as used
35 herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et

al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra). Representative groups of Ascomycota include, e.g., Neurospora, Eupenicillium (=Penicillium), Emericella (=Aspergillus), Eurotium (=Aspergillus), and the true yeasts listed above. Examples of Basidiomycota include mushrooms, rusts, and smuts. Representative groups of Chytridiomycota include, e.g., Allomyces, Blastocladiella, Coelomomyces, and aquatic fungi. Representative groups of Oomycota include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Examples of mitosporic fungi include Aspergillus, Penicillium, Candida, and Alternaria. Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.

The fungal host cell may be a yeast cell. "Yeast" as used herein includes ascosporeogenous yeast (Endomycetales), basidiosporeogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). The ascosporeogenous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of four subfamilies, Schizosaccharomycoidae (e.g., genus Schizosaccharomyces), Nadsonioideae, Lipomycoideae, and Saccharomycoidae (e.g., genera Pichia, Kluyveromyces and Saccharomyces). The basidiosporeogenous yeasts include the genera Leucosporidium, Rhodosporidium, Sporidiobolus, Filobasidium, and Filobasidiella. Yeast belonging to the Fungi Imperfecti are divided into two families, Sporobolomycetaceae (e.g., genera Sporobolomyces and Bullera) and Cryptococcaceae (e.g., genus Candida). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980. The biology of yeast and manipulation of yeast genetics are well known in

the art (see, e.g., Biochemistry and Genetics of Yeast, Bacil, M., Horecker, B.J., and Stopani, A.O.M., editors, 2nd edition, 1987; The Yeasts, Rose, A.H., and Harrison, J.S., editors, 2nd edition, 1987; and The Molecular Biology of the Yeast
5 *Saccharomyces*, Strathern et al., editors, 1981). The yeast host cell may be selected from a cell of a species of *Candida*, *Kluyveromyces*, *Saccharomyces*, *Schizosaccharomyces*, *Candida*, *Pichia*, *Hansenula*, , or *Yarrowia*. In a preferred embodiment, the yeast host cell is a *Saccharomyces carlsbergensis*,
10 *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cell. Other useful yeast host cells are a *Kluyveromyces lactis* *Kluyveromyces fragilis* *Hansenula polymorpha*, *Pichia pastoris* *Yarrowia lipolytica*,
15 *Schizosaccharomyces pombe*, *Ustilgo maylis*, *Candida maltose*, *Pichia guilliermondii* and *Pichia methanolio* cell (cf. Gleeson et al., J. Gen. Microbiol. 132, 1986, pp. 3459-3465; US 4,882,279 and US 4,879,231).

The fungal host cell may be a filamentous fungal cell.
20 "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a vegetative mycelium composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides.
25 Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative. In a more preferred embodiment, the filamentous fungal host
30 cell is a cell of a species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Hemicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, and *Trichoderma* or a teleomorph or synonym thereof. In an even more preferred embodiment, the filamentous fungal host cell is
35 an *Aspergillus* cell. In another even more preferred embodiment, the filamentous fungal host cell is an *Acremonium*

cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Fusarium* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Humicola* cell. In another even more preferred
5 embodiment, the filamentous fungal host cell is a *Mucor* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Myceliophthora* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Neurospora* cell. In another even more preferred embodiment,
10 the filamentous fungal host cell is a *Penicillium* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Thielavia* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Tolypocladium* cell. In another even more preferred embodiment, the
15 filamentous fungal host cell is a *Trichoderma* cell. In a most preferred embodiment, the filamentous fungal host cell is an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus niger*, *Aspergillus nidulans* or *Aspergillus oryzae* cell. In another most preferred embodiment,
20 the filamentous fungal host cell is a *Fusarium* cell of the section *Discolor* (also known as the section *Fusarium*). For example, the filamentous fungal parent cell may be a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*,
25 *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sulphureum*, or *Fusarium trichothecioides* cell. In another preferred embodiment, the filamentous fungal parent cell is a *Fusarium* strain of the section *Elegans*, e.g., *Fusarium*
30 *oxysporum*. In another most preferred embodiment, the filamentous fungal host cell is a *Humicola insolens* or *Humicola lanuginosa* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Mucor miehei* cell. In another most preferred embodiment, the filamentous fungal host
35 cell is a *Myceliophthora thermophilum* cell. In another most preferred embodiment, the filamentous fungal host cell is a

Neurospora crassa cell. In another most preferred embodiment, the filamentous fungal host cell is a Penicillium purpurogenum cell. In another most preferred embodiment, the filamentous fungal host cell is a Thielavia terrestris cell or a Acremonium
5 chrysogenum cell. In another most preferred embodiment, the Trichoderma cell is a Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei or Trichoderma viride cell.

The use of Aspergillus spp. for the expression of proteins
10 is described in, e.g., EP 272 277, EP 230 023. Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of Aspergillus host cells are described in EP
15 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81:1470-1474. A suitable method of transforming Fusarium species is described by Malardier et al., 1989, Gene 78:147-156 or in copending US Serial No. 08/269,449. Examples of other fungal cells are cells of filamentous fungi,
20 e.g. Aspergillus spp., Neurospora spp., Fusarium spp. or Trichoderma spp., in particular strains of A. oryzae, A. nidulans or A. niger. The transformation of F. oxysporum may, for instance, be carried out as described by Malardier et al., 1989, Gene 78: 147-156.

25 Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153:163; and
30 Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75:1920. Mammalian cells may be transformed by direct uptake using the calcium phosphate precipitation method of Graham and Van der Eb (1978, Virology 52:546).

The transformed or transfected host cells described above
35 are cultured in a suitable nutrient medium under conditions permitting the expression of the desired polypeptide, after

which the resulting polypeptide is recovered from the cells, or the culture broth.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or
5 complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The media are prepared using procedures known in the art (see, e.g., references for
10 bacteria and yeast; Bennett, J.W. and LaSure, L., editors, More Gene Manipulations in Fungi, Academic Press, CA, 1991).

If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell
15 lysates. The polypeptide are recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a
20 variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of polypeptide in question.

The polypeptides may be detected using methods known in
25 the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.

30 The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric
35 focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification,

J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Detailed description of the Invention

5 A method for increasing the number of copies of an amplification unit integrated into a host cell chromosome, according to the first, second, or third aspect of the invention.

In the industry there are a number of preferred bacterial
10 host cells, especially Gram-positive microorganisms are desirable.

Accordingly in a preferred embodiment the invention relates to the method of the first two aspects, wherein the host cell is a Gram-positive bacterial cell, preferably a
15 *Bacillus* cell, more preferably a *Bacillus* cell of a species chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus*
20 *megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; and most preferably a *Bacillus licheniformis* cell.

A host cell is susceptible to an inhibitory compound, if the host cell has reduced growth rate in the presence of the
25 compound when compared to the growth rate in the absence of the compound in a growth medium, or if the host cell becomes non-culturable in the presence of the compound, or if the host cell is killed in the presence of the compound. Antibiotics fall under this definition of inhibitory compounds however not all
30 inhibitory compounds are classified as classical antibiotics.

The inhibitory compound may be endogenously produced by the host cell as part of the host cell's normal metabolism, where the compound is normally not found in inhibitory concentrations. Rendering a chromosomal gene of the host cell
35 non-functional may result in the accumulation of an endogenously produced inhibitory compound within the host cell

resulting in an inhibitory concentration of the compound. In some cases the inhibitory compound is only produced in the host cell when the host cell is cultivated in the presence of a precursor. In a preferred embodiment of the invention the
5 inhibitory compound is UDP-galactose.

Preferable examples of precursors are galactose containing compounds - such as lactoses, melibioses, raffinoses, stachyoses, verbascoses and galactinola. More preferable precursors of galactose include alfa-lactose (beta-D-
10 galactopyranosyl-[1→4]-alfa-D-glucose), and other substrates which liberates free D-galactose upon hydrolysis by either alfa-galactosidases or beta-galactosidases. Other examples of potentially useful precursors for use in the method of the invention are chemically derivatised forms of galactose,
15 preferably chemical derivatives of D-galactose, from which D-galactose can be liberated by use of appropriate techniques, such as enzyme action, where the appropriate enzyme may be comprised in the medium or may be added to the medium or may indeed be secreted into the medium by the host cell. By way of
20 example suitable derivatives are D-galactose pentaacetate and D-galactose methyl galactoside. Preferably the medium may comprise a derivative of galactose, such as galactose-1-phosphate or UDP-galactose.

Accordingly in a preferred embodiment the invention
25 relates to the method of the first, second or third aspects, wherein the chromosomal gene of step a) encodes an enzyme, preferably chosen from the group consisting of galactokinase (EC 2.7.1.6), UTP-dependent pyrophosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), UDP-
30 galactose epimerase (EC 5.1.2.3); more preferably the chromosomal gene of step a) encodes an enzyme with UDP-galactose epimerase activity (EC 5.1.2.3), and most preferably the chromosomal gene of step a) is galE.

Further in a preferred embodiment the invention relates to
35 the method of the first, second, or third aspects, wherein the inhibitory compound is UDP-galactose.

Still further in a preferred embodiment the invention relates to the method of the first, second, or third aspects, wherein the precursor is free galactose, preferably free D-galactose; more preferably the precursor can be degraded to
5 produce free galactose, or preferably free D-galactose; even more preferably the precursor is lactose, melibiose, raffinose, stachyose, verbascose or galactinol.

Another preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the
10 medium comprises an enzyme capable of degrading the precursor to produce free galactose, or preferably free D-galactose.

One preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the host cell secretes an enzyme into the medium which is capable of
15 degrading the precursor to produce free galactose, or preferably free D-galactose, preferably the enzyme is a galactosidase, preferably an alfa-galactosidase or a beta-galactosidase.

As mentioned above this invention also concerns a nucleic
20 acid construct as defined elsewhere herein along with one or more components also described elsewhere herein that may be comprised in the construct.

Consequently a preferred embodiment of the invention relates to the method of the first, second, or third aspects,
25 wherein wherein the nucleic acid construct is a plasmid.

In a non-limiting example shown herein of the method of the invention it is demonstrated how antibiotic selectable markers may be comprised in the nucleic acid construct of the invention, and also how such markers may eventually be removed
30 from the host cell by the help of specific resolvase enzymes, a technique which is well known in the art.

Accordingly a preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the nucleic acid construct further comprises an
35 antibiotic selection marker, preferably flanked by by resolvase sites or res-sites.

As described supra chromosomal integration of a vector or a smaller part of a vector - such as an amplification unit as defined supra - into the genome of the host cell can be achieved by a number of ways. A non-limiting example of
5 integration by homologous recombination was shown herein.

A preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the amplification unit further comprises a nucleotide sequence with a homology to a chromosomal nucleotide sequence of the host
10 cell sufficient to effect chromosomal integration in the host cell of the amplification unit by homologous recombination, preferably the amplification unit further comprises a nucleotide sequence of at least 100 bp, preferably 200 bp, more preferably 300 bp, even more preferably 400 bp, and most
15 preferably at least 500 bp with an identity of at least 70%, preferably 80%, more preferably 90%, even more preferably 95%, and most preferably at least 98% identity to a chromosomal nucleotide sequence of the host cell.

In a non-limiting example integration into the chromosome
20 of a host cell can be selected for by first rendering a conditionally essential host cell gene non-functional as described elsewhere herein, thereby rendering the host cell selectable, then targetting the vector's integration by including on this a likewise non-functional copy of same host
25 gene of a size that allows homologous recombination between the two different copies of the non-functional host genes in the genome of the host cell and on the integration vector - where such a recombination will restore a functional copy of the gene, thus leaving the host cell selectable.

30 Accordingly a preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the nucleotide sequence comprised in the amplification unit is a partial non-functional copy of a conditionally essential gene of the host cell, wherein the host cell prior to
35 the first step of the invention has had the conditionally essential gene rendered non functional by a partial deletion,

and wherein a recombination event between the partial copy of the gene comprised in the amplification unit and the partial chromosomal gene restores a functional chromosomal gene; preferably the conditionally essential gene encodes a D-alanine
5 racemase, preferably the conditionally essential gene is dal.

Another preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein a first amplification unit integrates into the host cell chromosome by homologous recombination with the partially
10 deleted conditionally essential gene and renders the gene functional.

Yet another preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the amplification unit further comprises an antibiotic marker,
15 preferably flanked by resolvase sites or res-sites; preferably a host cell comprising a first chromosomally integrated amplification unit is selected and the antibiotic marker excised from the host cell chromosome by a resolvase prior to the next step in the method.

20 In the industrial production of polypeptides it is of interest to cultivate a host cell comprising several copies of a gene encoding a polypeptide of interest to achieve high yields. A preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the
25 gene of interest encodes an polypeptide of interest, preferably the polypeptide is an enzyme such as a protease; a cellulase; a lipase; a xylanase; a phospholipase; or preferably an amylase.

Another preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the
30 polypeptide is a hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.

In the present invention the expressably copy of a chromosomal gene as defined above is transcribed at a reduced level compared to the wild type level of the gene in the host
35 cell.

One preferred embodiment of the invention relates to the method of the first, second, or third aspects, wherein the expressable copy of the chromosomal gene comprised in an amplification unit integrated in the host cell chromosome has a
5 reduced transcription level compared to the transcription level of the wild type gene of the host cell, preferably the transcription level is reduced with a factor of 100, preferably 50, more preferably 10, even more preferably 5, and most preferably with a factor of 2; preferably the expressable copy
10 of the chromosomal gene comprised in the amplification unit is promoterless, more preferably the expressable copy of the chromosomal gene comprised in the amplification unit has a transcription terminator located upstream of the gene.

15 In a non-limiting example herein the gene of interest is located upstream from the expressable copy of the chromosomal gene and the two genes are co-transcribed from the promoter of the gene of interest.

A preferred embodiment of the invention relates to the
20 method of the first, second, or third aspects, wherein the gene of interest is located upstream of the expressable copy of the chromosomal gene within the amplification unit and wherein the two genes are co-directionally transcribed; preferably the expressable copy of the chromosomal gene is expressed by read-
25 through transcription from the gene of interest.

The method of the present invention provides a number of genetic tools that are advantageous in the invention. An amplification unit of the fourth aspect of the invention.

In a preferred embodiment the invention relates to the
30 amplification unit of the fourth aspect of the invention wherein the chromosomal gene encodes an enzyme, preferably chosen from the group consisting of galactokinase (EC 2.7.1.6), UTP-dependent pyrophosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), UDP-galactose
35 epimerase (EC 5.1.2.3); preferably the chromosomal gene encodes

an enzyme with UDP-galactose epimerase activity (EC 5.1.2.3); more preferably the chromosomal gene is galE.

In the industrial production of polypeptides it is of interest to cultivate a host cell comprising several copies of
5 a gene encoding a polypeptide of interest to achieve high yields.

Accordingly a preferred embodiment of the invention relates to the amplification unit of the fourth aspect of the invention wherein the gene of interest encodes an polypeptide
10 of interest; preferably the polypeptide is an enzyme such as a protease; a cellulase; a lipase; a xylanase; a phospholipase; or preferably an amylase.

Another preferred embodiment of the invention relates to the amplification unit of the fourth aspect of the invention
15 wherein the polypeptide is a hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.

Yet another preferred embodiment of the invention relates to the amplification unit of the fourth aspect of the invention wherein the expressable copy of the chromosomal gene is
20 promoterless; preferably the expressable copy of the chromosomal gene has a transcription terminator located upstream of the gene; and preferably the gene of interest is located upstream of the expressable copy of the chromosomal gene and wherein the two genes are co-directionally
25 transcribed, more preferably the expressable copy of the chromosomal gene is expressed by read-through transcription from the gene of interest.

A preferred embodiment of the invention relates to the amplification unit of the fourth aspect of the invention which
30 further comprises an antibiotic marker, preferably flanked by resolvase sites or res-sites.

As mentioned above the method of invention also provides a number of genetic tools, a nucleic acid construct comprising a unit as defined in any of the previous embodiments of the
35 fourth aspect.

The method of the invention provides a host cell of interest for the industry; a host cell wherein a chromosomal gene has been rendered non-functional leaving the host cell susceptible to an inhibitory compound endogenously produced by the host cell when cultivated in a medium comprising a precursor; and wherein the host cell comprises an amplification unit as defined in any of the embodiments of the fourth aspect or a nucleotide construct as defined in the fifth aspect.

Accordingly a preferred embodiment of the invention relates to the host cell of the sixth aspect, wherein the host cell is a Gram-positive bacterial cell, preferably a *Bacillus* cell, more preferably a *Bacillus* cell of a species chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; and most preferably a *Bacillus licheniformis* cell.

In another preferred embodiment the invention relates to the host cell of the sixth aspect, wherein the chromosomal gene encodes an enzyme, preferably the enzyme is chosen from the group of enzymes consisting of galactokinase (EC 2.7.1.6), UTP-dependent pyrophosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), UDP-galactose epimerase (EC 5.1.2.3), more preferably the enzyme is an UDP-galactose epimerase (EC 5.1.2.3), and most preferably the enzyme is encoded by *galE*.

In yet another preferred embodiment the invention relates to the host cell of the sixth aspect, where the inhibitory compound is UDP-galactose and preferably where the precursor is free galactose, preferably free D-galactose; even more preferably the precursor can be degraded to produce free galactose, or preferably free D-galactose; even more preferably the precursor is lactose, melibiose, raffinose, stachyose, verbascose or galactinol; yet even more preferably the medium

comprises an enzyme capable of degrading the precursor to produce free galactose, or preferably free D-galactose.

A preferred embodiment of the invention relates to the host cell of the sixth aspect, where the host cell secretes an enzyme into the medium which is capable of degrading the precursor to produce free galactose, or preferably free D-galactose; more preferably the enzyme is a galactosidase, preferably an alfa-galactosidase or a beta-galactosidase.

Another preferred embodiment of the invention relates to the host cell of the sixth aspect, wherein the amplification unit further comprises a nucleotide sequence of at least 100 bp, preferably 200 bp, more preferably 300 bp, even more preferably 400 bp, and most preferably at least 500 bp with an identity of at least 70%, preferably 80%, more preferably 90%, even more preferably 95%, and most preferably at least 98% identity to a chromosomal nucleotide sequence of the host cell.

A preferred embodiment of the invention relates to the host cell of the sixth aspect, wherein the nucleotide sequence comprised in the amplification unit is a partial non-functional copy of a conditionally essential gene of the host cell, wherein the host cell has had the conditionally essential gene rendered non functional by a partial deletion, and wherein a recombination event between the partial copy of the gene comprised in the amplification unit and the partial chromosomal gene has restored a functional chromosomal gene; preferably the conditionally essential gene encodes a D-alanine racemase, preferably the conditionally essential gene is dal.

Another preferred embodiment of the invention relates to the host cell of the sixth aspect, wherein the expressable copy of the chromosomal gene of the amplification unit has a reduced transcription level compared to the transcription level of the wild type gene of the host cell, preferably the transcription level is reduced with a factor of 100, preferably 50, more preferably 10, even more preferably 5, and most preferably with a factor of 2.

Finally the invention provides a process for producing a polypeptide of interest, wherein the process comprises a step of cultivating a host cell as defined in any of the embodiments of the sixth aspect.

5 Accordingly a preferred embodiment of the invention relates to the process of the final aspect, wherein the polypeptide is an enzyme such as a protease; a cellulase; a lipase; a xylanase; a phospholipase; or preferably an amylase..

Another preferred embodiment of the invention relates to
10 the process of the final aspect, wherein the polypeptide is a hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.

15 Introduction to Examples

In order to use the *galE* gene as a marker in *B. subtilis*, it is necessary to delete the native *galE* gene on the chromosome. This mutant will be tested on different medias with and without galactose and glucose to confirm the phenotype.

20 To enable an evaluation of the *galE* gene as an amplification marker, we decided to subclone the gene on an amplification vector comprising an AA560 amylase encoding gene as a reporter enzyme to determine the actual expression level of clones with single and multiple copies. Selection for
25 multiple copies of the *galE* gene requires that the gene is expressed at a very low level. A weakly expressed *galE* gene will assure that only clones with many copies and sufficient expression of the epimerase will allow growth in the presence of galactose. The subduing of *galE* expression is done by
30 subcloning *galE* without expression signals downstream of the transcriptional terminator of the AA560 amylase gene. Transcription of *galE* is then dependant of the AA560 promoter and the very limited transcriptional read-through of the terminator.

35 The amplification vector also comprises the C-terminal part of the *dal* gene which can complement a *dal*-minus *B.*

subtilis with a C-terminal deletion of the dal gene. Transformation of the dal-minus B. subtilis with this amplification plasmid will enable direct selection for integration at the dal locus, when plated on media without D-
5 alanine.

Materials and Methods

10 Strains and Donor Organisms

Bacillus subtilis PL1801: This strain is a B.subtilis DN1885 which has disrupted apr and npr genes (Diderichsen, B et al. 1990. Cloning of aldB, which encodes alpha-acetolactate decarboxylase, an exoenzyme from Bacillus brevis. J.
15 Bacteriol., 172, 4315-4321).

B. subtilis DN1886: This strain is a B. subtilis DN1885 with a disrupted dal gene.

B.subtilis PL1955: This strain is a B.subtilis PL1801 carrying the plasmid pE194 which can deliver the RepF protein
20 to support replication of replication-minus pE194 derivatives lacking the repF gene.

B.subtilis MOL1794: This strain is a B. subtilis PL1801 where the gale gene was replaced with a kanamycine resistance gene by use of the plasmid pMOL1748 (SEQ ID 1).

25 B.subtilis MOL1805: This strain is a DN1686 (dal-) strain where the gale gene was replaced with a kanamycine resistance gene.

B.subtilis MOL1875: This strain is a MOL1805 where the kanamycine resistance gene gene was excised (dal-, gale-, no
30 antibiotic markers).

Plasmids

pMOL1748 (SEQ ID 1): This plasmid is a pE194 derivative (Horinouchi, S and Weisblum, B., 1982, J.Bacteriol. 150:804-
35 814) essentially containing elements making the plasmid

propagatable in *Bacillus subtilis*, a kanamycin resistance gene, a gene conferring resistance to erythromycin, two flanking fragments from *B. subtilis* *galE* inserted upstream and downstream of the kanamycin resistance gene, two direct
 5 repeats that signify the *res* site from pAM β 1 and a fragment from pUB110 coding for the origin of transfer (McKenzie, T. et al., 1986, Plasmid 15:93-103). This plasmid is used for deleting the *galE* gene in the *B. subtilis* strains PL1801 and DN1686.

10 Table 1: pMOL1748 (6405 bp)

Position (bp)	Size (bp)	Element (bp)	Origin
429-432	4	Linker	Synthetic
433-605	173	<i>res</i> site from pAM β 1	<u>E. faecalis</u>
606-978	373	Downstream <i>galE</i> seq	<u>B. subtilis</u>
979-1038	60	Linker	Synthetic
1039-4768	3730	pE194	<u>S. aureus</u>
4769-4779	11	Linker sequence	Synthetic
4780-5317	538	pUB110	<u>S. aureus</u>
5318-5342	25	Linker	Synthetic
5343-5666	324	Upstream <i>galE</i> seq.	<u>B. subtilis</u>
5667-5685	19	Linker	<u>Synthetic</u>
5686-5858	173	<i>res</i> site from pAM β 1	<u>E. faecalis</u>
5859-5864	6	Linker	<u>Synthetic</u>
5865-428	969	pUB110 (Kan gene)	<u>S. aureus</u>

pMOL1807 (SEQ ID 2) and pMOL1809 (SEQ ID 3): These plasmids are replication-minus pE194 derivatives (Horinouchi, S and Weisblum, B., 1982, J.Bacteriol. 150:804-814) containing
 15 the origin of replication but lacking the *repF* gene coding for the replication protein. The *repF* deleted plasmid is totally dependant on replication protein delivered in trans from either a second plasmid or a chromosomally encoded *repF* gene in order to replicate. The plasmids codes for the kanamycin resistance
 20 gene, an alfa-amylase designated AA560, a promoterless *galE*

gene of *B. subtilis*, the C-terminal part of a *dal* gene for complementation of the *dal*-minus phenotype in DN1686 and derivatives thereof (such as MOL1875). The *alfa*-amylase gene and the *galE* gene are transcriptionally fused in both plasmids but the pMOL1807 (SEQ ID 2) plasmid also has a transcriptional terminator located between the two genes, which only allows minor transcriptional read-through. These plasmids are used for integration and amplification studies in the *dal* locus of MOL1875.

10 Table 2: pMOL1807 (5943 bp)

Position (bp)	Size (bp)	Element (bp)	Origin
5-828	824	C-terminal <i>dal</i> sequence	<i>B. subtilis</i>
829-833	5	Linker sequence	Synthetic
834-2045	1212	pUB110 (Kana)	<i>S. aureus</i>
2046-2066	21	Linker sequence	Synthetic
2067-2316	250	pE194 (ori)	<i>S. aureus</i>
2317-2328	12	Linker sequence	Synthetic
2329-2884	556	pUB110 (oriT)	<i>S. aureus</i>
2885-2904	20	Linker sequence	Synthetic
2905-3167	263	<i>amyL</i> promoter and signal peptide	<i>B. licheniformis</i>
3168-3176	9	Linker sequence	Synthetic
3177-4631	1455	α -amylase AA560 (NN5820)	<i>B. species</i>
4632-4660	29	Linker sequence	Synthetic
4661-4776	116	<i>AmyL</i> terminator	<i>B. licheniformis</i>
4777-4803	27	Linker sequence	Synthetic
4804-5942	1139	<i>galE</i>	<i>B. subtilis</i>
5943-4	5	Linker sequence	Synthetic

Table 3: pMOL1809 (5793 bp)

Position (bp)	Size (bp)	Element (bp)	Origin
5-828	824	C-terminal dal sequence	<u>B. subtilis</u>
829-833	5	Linker sequence	Synthetic
834-2045	1212	pUB110 (Kana)	S. aureus
2046-2066	21	Linker sequence	Synthetic
2067-2316	250	pE194 (ori)	S. aureus
2317-2328	12	Linker sequence	Synthetic
2329-2884	556	pUB110 (oriT)	S. aureus
2885-2904	20	Linker sequence	Synthetic
2905-3167	263	amyL promoter and signal peptide	<u>B. licheniformis</u>
3168-3176	9	Linker sequence	Synthetic
3177-4631	1455	□-amylase AA560 (NN5820)	<u>B. species</u>
4632-4653	22	Linker sequence	Synthetic
4654-5792	1139	AmyL terminator	<u>B. licheniformis</u>
5793-4	5	Linker sequence	Synthetic

pWT: a temperature sensitive, high copy number pAMβ1 derivative plasmid comprising a gene coding for the resolvase enzyme from pAMBeta1 which can act on resolvase recognition sites (res) and an Erm resistance marker.

Media

10 TY (as described in Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995).

LB agar (as described in Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995). LBP is LB agar supplemented with 0.05 M potassium phosphate, pH 7.0. LBPG is LB agar supplemented with 0.5% 15 Glucose and 0.05 M potassium phosphate, pH 7.0. LBPSK is LB

agar supplemented with 0.05 M potassium phosphate, pH 7.0 and 1% of skimmed milk.

BPX media is described in EP 0 506 780 (WO 91/09129).

TSS agar (as described in Fouet A. and Sonenshein, A. L. (1990) A Target for Carbon Source-Dependant Negative Regulation of the *citB* Promoter of *Bacillus subtilis*. J. Bacteriol., 172, 835-844).

TSSara medium is TSS medium supplemented with 0.2% arabinose

When appropriate, glucose was replaced with 0.5% galactose unless otherwise stated. For plates, 2% agar was added for solid media. For amylase phenotypic detection the plates were supplemented with 0.2% starch. When appropriate 10 mg/ml kanamycine was added.

15

Propagation of PL1801 strain.

The *Bacillus subtilis* strain PL1801 was propagated in liquid medium 3 as specified by ATCC (American Type Culture Collection, USA). After 18 hours incubation at 37°C and 300 rpm, the cells were harvested, and genomic DNA was isolated by the method described below.

Genomic DNA Preparation

The *Bacillus subtilis* strain PL1801 was propagated in liquid media as described above. The cells were harvested, and genomic DNA was isolated by the method described by Pitcher et al. 1989. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate; Lett Appl Microbiol 8:151-156.

General molecular biology methods

Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular biology (Sambrook et al. 1989. Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in

Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

Competent cells were prepared and transformed as described by Yasbin, R.E. et al. 1975. Transformation and transfection in lysogenic strains of *Bacillus subtilis*: evidence for selective induction of prophage in competent cells. J. Bacteriol, 121:296-304.

Enzymes for DNA manipulations were used according to the specifications of the suppliers (e.g. restriction endonucleases, ligases etc. are obtainable from New England Biolabs, Inc.).

PCR reactions were performed using High Fidelity DNA Polymerase (Boeringer Mannheim) according to manufacturers instructions. The PCR reaction was set up in PCR buffer containing 200 μ M of each dNTP, 2.5 units of High Fidelity DNA Polymerase and 100 pmol of each primer.

The PCR reactions were performed using a DNA thermal cycler PTC-200 (MJ Research). One incubation at 94°C for 1 min followed by thirty cycles of PCR performed using a cycle profile of denaturation at 94°C for 10 sec, annealing at 60°C for 30 sec, and extension at 72°C for 2 min. Five- μ l aliquots of the amplification product were analysed by electrophoresis in 0.7 % agarose gels (NuSieve, FMC) to verify a DNA fragment of the correct size.

Fermentations

Fermentations to evaluate amylase yields were performed in shakeflasks with 100 ml BPX at 30°C, 300 rpm for five days. Culture volumes of 10 ml were harvested and centrifuged at 10.000 g to remove cells and debris. The clear supernants were used for assaying alfa-amylase activity or were loaded on SDS gels.

Assay for a-amylase activity

Alfa-amylase activity was determined by a method employing an enzymatic colorimetric test with 4,6-ethylidene(G7)-p-nitrophenyl(G1)- α ,D-maltoheptaoside (ethylidene-G7PNP) as substrate (Boehringer Mannheim, Germany art. 1442309). Under a
5 specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given alfa-amylase will hydrolyse a certain amount of substrate and a yellow colour will be produced. The colour intensity is measured at 405 nm. The measured absorbance is directly proportional to the activity of
10 the alfa-amylase in question under the given set of conditions.

SDS-page

SDS-page was performed on a Novex (Novex, San Diego) gradient Tricine 10-20% gel under denaturing conditions as
15 prescribed by manufacturer.

EXAMPLES

20 Deletion of gale in B. subtilis

A temperature sensitive plasmid was constructed for the purpose of deleting the gale gene in B. subtilis. Two flanking sequences upstream and downstream of the gale gene were amplified by PCR and inserted on each side of a kanamycine
25 (Kan) marker in the plasmid which further comprised an erythromycine (Erm) resistance marker. The primer sequences used in the PCR amplifications are as follows:

Upstream gale fragment:

30 B5860H10 (SEQ ID 4): TTACATCCGCGGGTGAGGAAAGACAGGAC
B5860H11 (SEQ ID 5): TAGTGAATTTCAGAACCGGTCCACATCC

Downstream gale fragment:

181804 (SEQ ID 6): TGTTCCCGAGAATGGAGGCCTTCTCAATTG
35 181805 (SEQ ID 7): TGGTTGTCGACATCTGAGGGAGGTACAATTGTAGCTG

The resulting plasmid pMOL1748 (SEQ ID 1) was transferred to *B. subtilis* PL1801 and plated on LBPG media with 5µg/ml erythromycin (Erm). The colonies were re-streaked twice on plates at 50°C to select for integration of the plasmid at the *galE* locus. The clones were grown in plain TY at 33°C over 4 days to allow for excision and loss of the plasmid leaving the Kan marker in place of the *galE* gene. The strain MOL1794 was screened as being Kan resistant and Erm sensitive.

A *galE* deletion strain designated MOL1794 was tested on selective TSS minimal media supplemented with 0.2% galactose and 0.2% gluconate. The original *B. subtilis* PL1801 (*galE*+) strain showed fine growth on these plates while the *galE*- strain MOL 1794 showed no growth even after several days of incubation. On control TSS plates supplemented with 0.2% gluconate, both strains grew. The reported toxic effect of galactose on a *galE*- strain is therefore confirmed.

The *galE* deletion was transferred to an isogenic D-alanine racemase negative (*dal*-) strain designated DN 1886 by simple chromosomal transformation and selection for transfer of the Kan resistance. A *dal*- *galE*- strain was isolated and designated MOL1805.

The Kan resistance marker located in the *galE* locus of MOL1794 and MOL1805 was flanked by resolvase recognition sites (*res*) which allow a specific excision reaction in the presence of a resolvase. In order to remove the Kan marker from the chromosome, MOL1794 and MOL1805 were both transformed with pWT which is a temperature sensitive plasmid comprising a gene coding for resolvase and an Erm resistance marker. Transformants were selected on plates with 5µg/ml Erm, they were tested for loss of the Kan marker and further re-streaked twice on plates with no antibiotics at 50°C to cure the strains of the pWT plasmid. Selected clones were screened for loss of Erm resistance and Kan resistance and were designated MOL1875 (DN1886, *dal*-, *galE*-; no antibiotic markers) and MOL1877 (PL1801, *galE*-; no antibiotic markers).

Amplification plasmids

Two different amplification plasmids with (pMOL1807; SEQ ID 2) and without (pMOL1809; SEQ ID 3) a transcriptional terminator between the AA560 amylase encoding gene and galeE were constructed. The PCR-primers used for fragment amplification in the construction of the plasmids were as follows:

C-terminal dal fragment:

10 188502 (SEQ ID 8): TTTTCATCGATACTAGTGTGCACGGATCCATCTGAAGGTCG
ATACGGG

188836 (SEQ ID 9): TTGTTTGTGCGACGCAAAGCTGTTTTATGAATTCTCC

galeE fragment primers:

15 190694 (SEQ ID 10): TTTTGGCCCAGCCGGCCAACAGGTCATTTTTTAGGAGGG
190695 (SEQ ID 11): TTATTGGATCCGTGAAAATCAAATAACAGCTAACAAGGG
190697 (SEQ ID 12): TTTTCATCGATAACAGGTCATTTTTTAGGAGGG

20 Amplification experiments

The two amplification plasmids pMOL1807 (SEQ ID 2) and pMOL1809 (SEQ ID 3) were introduced by transformation into MOL1875 (dal-, gale-) and plated on solid LBPA media (LB + phosphate + 0.2 % starch) without D-alanine to select for
25 complementation of the dal phenotype. Transformants growing on these plates had integrated the plasmids into the dal locus and converted the dal- phenotype to dal+. All transformants showed clearing zones on the starch medium plates which indicated integration and expression of the AA560 amylase also. The site
30 of integration was verified by PCR and the clones were re-streaked on TSSara minimal media both with and without galactose to study the galeE expression. Clones with integration of pMOL1807 (SEQ ID 2) holding the terminator between the AA560 amylase and the galeE gene showed no growth on galactose plates.
35 This phenotype demonstrated that a single copy of the artificial AA560-galeE fusion in this construct did not express

sufficient Gale epimerase to remove the toxic UDP-galactose that was accumulated in the cells in the presence of galactose. The other construction, pMOL1809 (SEQ ID 3) without a transcriptional terminator between the two genes showed some growth on TSS plates with galactose. From these results it was clear that pMOL1807 (SEQ ID 2) had the potential to be used as an amplification unit in the presence of galactose.

The amplification procedure using galactose as the active agent can be performed in many different ways using both plates and broth cultures with different levels of galactose and other sugar compounds or precursors from which free galactose can be released. We performed a number of different amplification procedures to evaluate their efficiency. The following table is a thorough description of the different amplification steps each transformant goes through before inoculation in a shakeflask (100 ml BPX). The Kan marker makes it possible to amplify by using Kan in the traditional way and then to compare the amplification efficiency to the galactose method of the invention.

20

#	Amplification method	KNU(T)/g
1	Transformant directly from LBPA	2.54
2	Transformant directly from LBPA	2.16
3	Transformant on LBPA, re-streaked 3 x	2.01
4	MOL1815 (single copy transformant)	3.63
5	Transformant on LBPA >re-streaked on TSS + 0.2% ara + 0.5% gal	5.09
6	as # 5 + 2% gal in shakeflask	4.53
7	Transformant on LBPA >2x(innoc. in liquid TSS + 0.2% ara + 0.5% gal) >2x(re-streaked on TSS + 0.2% ara + 0.5% gal)	4.77
8	as # 8 + 0.5% gal in shakeflask	5.66
9	Transformant on LBPA >re-streaked on TSS + 0.2% ara + 0.5% gal >2x(innoc. in liquid TY+ 0.5% gal) >2x(re-streaked on TSS + 0.2% ara + 0.5% gal)	7.10
10	as # 9 + 0.5% gal in shakeflask	2.09

11	Transformant on LBPA >re-streaked on TSS + 0.2% ara + 0.5% gal >2x(innoc. in liquid TY+ 0.5% gal) >2x(re-streaked on LBPA)	6.70
12	as # 11 + 0.5% gal in shakeflask	4.35
13	Transformant on LBPA >re-streaked on TSS + 0.2% ara + 0.5% gal >2x(innoc. in liquid TY+ 50µg/ml Kan) >re-streaked on LBPA+ 50µg/ml Kan >re-streaked on LBPA	7.71
14	as # 13 + 20 µg/ml Kan in shakeflask	11.60
15	as # 9	6.65
16	as # 10	5.16
17	as # 11	12.10
18	as # 12	9.40
19	as # 13	7.10
20	as # 14	6.30
21	Transformant on TSSA + 0.2% ara + 0.5% gal >2x(re-streaked on TSSA + 0.2% ara + 0.5% gal)	4.30
22	as # 21 + 0.5% gal in shakeflask	5.60
23	as # 21	2.90
24	as # 22	5.00
25	Transformant on TSSA + 0.2% ara + 2% gal >2x(re-streaked on TSSA + 0.2% ara + 2% gal)	3.60
26	as # 25 + 0.5% gal in shakeflask	5.80
27	as # 25	5.00
28	as # 26	4.40

Table 4: The table shows the amplification method of individual clones and the actual amylase yields from a 5 day fermentation in 100 ml SK1-M medium at 300C. Some of the fermentations were performed in the presence of galactose or Kan to select for multiple copies during the fermentations. From the table it is obvious that amplification protocols using Kan or galactose in TY full broth show the highest yields (in bold). These results show that yield improvements by adding galactose is as efficient as using Kan.

The Southern blot in figure 1 shows samples from different strains either amplified by use of galactose or kanamycine or strains where no selection pressure is opposed.

The results summarized herein show that it is indeed
5 possible to increase the copy number of a chromosomally integrated expression cassette holding the galE gene by adding a simple sugar compound such as galactose to the growth medium. The amplification potential, as judged from the band intensity on the Southern blots (figure 1) and the fermentation yields
10 (table 4), is very similar to what can be achieved by the traditional kanamycine antibiotic selection/amplification.

Claims

1. A method for increasing the number of copies of an amplification unit integrated into a host cell chromosome, wherein the method comprises the steps of:

- 5 a) rendering a chromosomal gene of a host cell non-functional, wherein the host cell becomes susceptible to an inhibitory compound endogenously produced by the host cell when the host cell is cultivated in a medium comprising a precursor;
- 10 b) making a nucleic acid construct comprising an amplification unit, wherein the unit comprises:
 - i) an expression cassette comprising at least one copy of a gene of interest; and
 - 15 ii) an expressible copy of the chromosomal gene of step a), wherein the unit integrates into the host cell chromosome;
- c) introducing the nucleic acid construct of step b) into the host cell of step a), wherein at least one copy of the amplification unit integrates into the host cell chromosome;
- 20 d) cultivating the host cell of step c) in a medium comprising the precursor, wherein a chromosomally integrated copy of the amplification unit is duplicated or multiplied on the host cell chromosome;
- 25 e) selecting a host cell comprising two or more chromosomally integrated copies of the amplification unit; and optionally
- f) performing one or more cycles of steps d) and e) using the host cell selected in step e) in each new cycle; wherein the number of chromosomally integrated copies of the
- 30 amplification unit increases with each repeat.

2. A method for constructing a host cell comprising at least one copy of an amplification unit integrated into the host cell chromosome, wherein the method comprises the steps of:

- 35 a) rendering a chromosomal gene of a host cell non-functional, wherein the host cell becomes susceptible to an

inhibitory compound endogenously produced by the host cell when the host cell is cultivated in a medium comprising a precursor;

- 5 b) making a nucleic acid construct comprising an amplification unit, wherein the unit comprises:
- i) an expression cassette comprising at least one copy of a gene of interest; and
- ii) an expressable copy of the chromosomal gene of step a), wherein the unit integrates into the host cell
- 10 chromosome;
- c) introducing the nucleic acid construct of step b) into the host cell of step a) and cultivating the host cell in a medium comprising the precursor, wherein at least one copy of the amplification unit integrates into the host cell
- 15 chromosome; and
- d) selecting a host cell comprising at least one chromosomally integrated copy of the amplification unit.

3. A method for increasing the number of copies of an

20 amplification unit integrated into a host cell chromosome, wherein the method comprises the steps of:

- a) providing a host cell, wherein a chromosomal gene has been rendered non-functional, whereby the host cell becomes susceptible to an inhibitory compound endogenously produced
- 25 by the host cell when the host cell is cultivated in a medium comprising a precursor;
- b) introducing a nucleic acid construct into the host cell of step a), the nucleic acid construct comprising an amplification unit, wherein the unit comprises:
- 30 i) an expression cassette comprising at least one copy of a gene of interest; and
- ii) an expressable copy of the chromosomal gene of step a),
- wherein at least one copy of the amplification unit
- 35 integrates into the host cell chromosome;

- c) cultivating the host cell of step b) in a medium comprising the precursor, wherein a chromosomally integrated copy of the amplification unit is duplicated or multiplied on the host cell chromosome;
- 5 d) selecting a host cell comprising two or more chromosomally integrated copies of the amplification unit; and optionally
- e) performing one or more cycles of steps c) and d) using the host cell selected in step d) in each new cycle; wherein the number of chromosomally integrated copies of the
- 10 amplification unit increases with each cycle.

4. The method of any of claims 1 - 3, wherein the host cell is a Gram-positive bacterial cell, preferably a *Bacillus* cell, more preferably a *Bacillus* cell of a species chosen from the

15 group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus*

20 *thuringiensis*; and most preferably a *Bacillus licheniformis* cell.

5. The method of any of claims 1 - 4, wherein the chromosomal gene of step a) encodes an enzyme, preferably chosen from the

25 group consisting of galactokinase (EC 2.7.1.6), UTP-dependent pyrophosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), UDP-galactose epimerase (EC 5.1.2.3).

30 6. The method of any of claims 1 - 4, wherein the chromosomal gene of step a) encodes an enzyme with UDP-galactose epimerase activity (EC 5.1.2.3).

7. The method of any of claims 1 - 4, wherein the chromosomal

35 gene of step a) is *galE*.

8. The method of any of claims 1 - 7, wherein the inhibitory compound is UDP-galactose.

9. The method of any of claims 1 - 8, wherein the precursor is
5 free galactose, preferably free D-galactose.

10. The method of any of claims 1 - 8, wherein the precursor can be degraded to produce free galactose, or preferably free D-galactose.

10

11. The method of any of claims 1 - 8, wherein the precursor is lactose, melibiose, raffinose, stachyose, verbascose or galactinol.

15 12. The method of any of claims 1 - 8, wherein the medium comprises an enzyme capable of degrading the precursor to produce free galactose, or preferably free D-galactose.

13. The method of any of claims 1 - 8, wherein the host cell
20 secretes an enzyme into the medium which is capable of degrading the precursor to produce free galactose, or preferably free D-galactose.

14. The method of claims 12 or 13, wherein the enzyme is a
25 galactosidase, preferably an alfa-galactosidase or a beta-galactosidase.

15. The method of any of claims 1 - 14, wherein the nucleic acid construct is a plasmid.

30

16. The method of any of claims 1 - 15, wherein the nucleic acid construct further comprises an antibiotic selection marker, preferably flanked by by resolvase sites or res-sites.

35 17. The method of any of claims 1 - 15, wherein the amplification unit further comprises a nucleotide sequence with

a homology to a chromosomal nucleotide sequence of the host cell sufficient to effect chromosomal integration in the host cell of the amplification unit by homologous recombination.

- 5 18. The method of any of claims 1 - 15, wherein the amplification unit further comprises a nucleotide sequence of at least 100 bp, preferably 200 bp, more preferably 300 bp, even more preferably 400 bp, and most preferably at least 500 bp with an identity of at least 70%, preferably 80%, more
10 preferably 90%, even more preferably 95%, and most preferably at least 98% identity to a chromosomal nucleotide sequence of the host cell.
19. The method of claims 17 or 18, wherein the nucleotide
15 sequence comprised in the amplification unit is a partial non-functional copy of a conditionally essential gene of the host cell, wherein the host cell prior to the first step of the invention has had the conditionally essential gene rendered non functional by a partial deletion, and wherein a recombination
20 event between the partial copy of the gene comprised in the amplification unit and the partial chromosomal gene restores a functional chromosomal gene.
20. The method of claim 19, wherein the conditionally essential
25 gene encodes a D-alanine racemase, preferably the conditionally essential gene is dal.
21. The method of claim 19 or 20, wherein a first amplification unit integrates into the host cell chromosome by homologous
30 recombination with the partially deleted conditionally essential gene and renders the gene functional.
22. The method of any of claims 1 - 21, wherein the amplification unit further comprises an antibiotic marker,
35 preferably flanked by resolvase sites or res-sites.

23. The method of claim 22, wherein a host cell comprising a first chromosomally integrated amplification unit is selected and the antibiotic marker excised from the host cell chromosome by a resolvase prior to the next step in the method.
- 5 24. The method of any of claims 1 - 23, wherein the gene of interest encodes an polypeptide of interest.
25. The method of claim 24, wherein the polypeptide is an
10 enzyme such as a protease; a cellulase; a lipase; a xylanase; a phospholipase; or preferably an amylase.
26. The method of claim 24, wherein the polypeptide is a
15 hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.
27. The method of any of claims 1 - 26, wherein the expressable copy of the chromosomal gene comprised in an amplification unit integrated in the host cell chromosome has a reduced
20 transcription level compared to the transcription level of the wild type gene of the host cell, preferably the transcription level is reduced with a factor of 100, preferably 50, more preferably 10, even more preferably 5, and most preferably with a factor of 2.
- 25 28. The method of any of claims 1 - 27, wherein the expressable copy of the chromosomal gene comprised in the amplification unit is promoterless.
- 30 29. The method of any of claims 1 - 28, wherein the expressable copy of the chromosomal gene comprised in the amplification unit has a transcription terminator located upstream of the gene.
- 35 30. The method of any of claims 1 - 29, wherein the gene of interest is located upstream of the expressable copy of the

chromosomal gene within the amplification unit and wherein the two genes are co-directionally transcribed.

31. The method of claim 30, wherein the expressable copy of the
5 chromosomal gene is expressed by read-through transcription from the gene of interest.

32. An amplification unit comprising:

- 10 a) an expression cassette comprising at least one copy of a gene of interest; and
- b) an expressable copy of a conditionally essential chromosomal gene of a host cell; wherein the unit integrates into the host cell chromosome upon introduction of the nucleic acid construct into the host cell.

15

33. The unit of claim 32, wherein the chromosomal gene encodes an enzyme, preferably chosen from the group consisting of galactokinase (EC 2.7.1.6), UTP-dependent pyrophosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC
20 2.7.7.12), UDP-galactose epimerase (EC 5.1.2.3).

34. The unit of claims 32 or 33, wherein the chromosomal gene encodes an enzyme with UDP-galactose epimerase activity (EC 5.1.2.3).

25

35. The unit of claims 32 or 33, wherein the chromosomal gene is galE.

36. The unit of any of claims 32 - 35, wherein the gene of
30 interest encodes a polypeptide of interest.

37. The unit of claim 36, wherein the polypeptide is an enzyme such as a protease; a cellulase; a lipase; a xylanase; a phospholipase; or preferably an amylase.

35

38. The unit of claim 36, wherein the polypeptide is a hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.

5 39. The unit of any of claims 32 - 38, wherein the expressable copy of the chromosomal gene is promoterless.

40. The unit of any of claims 32 - 39, wherein the expressable copy of the chromosomal gene has a transcription terminator
10 located upstream of the gene.

41. The unit of any of claims 32 - 40, wherein the gene of interest is located upstream of the expressable copy of the chromosomal gene and wherein the two genes are co-directionally
15 transcribed.

42. The unit of claim 41, wherein the expressable copy of the chromosomal gene is expressed by read-through transcription from the gene of interest.

20

43. The unit of any of claims 32 - 42, which further comprises an antibiotic marker, preferably flanked by resolvase sites or res-sites.

25 44. A nucleic acid construct comprising a unit as defined in any of claims 32 - 43.

45. A host cell wherein a chromosomal gene has been rendered non-functional leaving the host cell susceptible to an
30 inhibitory compound endogenously produced by the host cell when cultivated in a medium comprising a precursor; and wherein the host cell comprises an amplification unit as defined in any of claims 32 - 43 or a nucleotide construct as defined in claim
44.

35

46. The host cell of claim 45, wherein the host cell is a Gram-positive bacterial cell, preferably a *Bacillus* cell, more preferably a *Bacillus* cell of a species chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*,
5 *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; and most preferably a *Bacillus licheniformis*
10 cell.

47. The host cell of claims 45 or 46, wherein the chromosomal gene encodes an enzyme, preferably the enzyme is chosen from the group of enzymes consisting of galactokinase (EC 2.7.1.6),
15 UTP-dependent pyrophosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), UDP-galactose epimerase (EC 5.1.2.3), more preferably the enzyme is an UDP-galactose epimerase (EC 5.1.2.3), and most preferably the enzyme is encoded by *galE*.

20

48. The host cell of any of claims 45 - 47, where the inhibitory compound is UDP-galactose.

49. The host cell of any of claims 45 - 48, where the precursor
25 is free galactose, preferably free D-galactose.

50. The host cell of any of claims 45 - 48, where the precursor can be degraded to produce free galactose, or preferably free D-galactose.

30

51. The host cell of any of claims 45 - 48, where the precursor is lactose, melibiose, raffinose, stachyose, verbascose or galactinol.

52. The host cell of any of claims 45 - 51, where the medium comprises an enzyme capable of degrading the precursor to produce free galactose, or preferably free D-galactose.

5 53. The host cell of any of claims 45 - 52, where the host cell secretes an enzyme into the medium which is capable of degrading the precursor to produce free galactose, or preferably free D-galactose.

10 54. The host cell of claims 52 or 53, where the enzyme is a galactosidase, preferably an alfa-galactosidase or a beta-galactosidase.

55. The host cell of any of claims 45 - 54, wherein the
15 amplification unit further comprises a nucleotide sequence of at least 100 bp, preferably 200 bp, more preferably 300 bp, even more preferably 400 bp, and most preferably at least 500 bp with an identity of at least 70%, preferably 80%, more preferably 90%, even more preferably 95%, and most preferably
20 at least 98% identity to a chromosomal nucleotide sequence of the host cell.

56. The host cell of claim 55 wherein the nucleotide sequence comprised in the amplification unit is a partial non-functional
25 copy of a conditionally essential gene of the host cell, wherein the host cell has had the conditionally essential gene rendered non functional by a partial deletion, and wherein a recombination event between the partial copy of the gene comprised in the amplification unit and the partial chromosomal
30 gene has restored a functional chromosomal gene.

57. The host cell of claim 56 wherein the conditionally essential gene encodes a D-alanine racemase, preferably the conditionally essential gene is dal.


58. The host cell of any of claims 45 - 57 wherein the expressable copy of the chromosomal gene of the amplification unit has a reduced transcription level compared to the transcription level of the wild type gene of the host cell, 5 preferably the transcription level is reduced with a factor of 100, preferably 50, more preferably 10, even more preferably 5, and most preferably with a factor of 2.

59. A process for producing a polypeptide of interest, wherein 10 the process comprises a step of cultivating a host cell as defined in any of claims 45 - 58.

60. The process of claim 59 wherein the polypeptide is an enzyme such as a protease; a cellulase; a lipase; a xylanase; a 15 phospholipase; or preferably an amylase.

61. The process of claim 59 wherein the polypeptide is a hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.

1/1

Figure 1

Southern analysis on different amplified clones.
Numbers in parenthesis refer to the clone numbers in table 1.

- | | |
|----------|-------------------------------|
| Lane 1: | Marker, Lambda-HindIII digest |
| Lane 2: | PL1801 |
| Lane 3: | Two copy strain |
| Lane 4: | Singlecopy strain (#2) |
| Lane 5: | Multicopy by galactose (#9) |
| Lane 6: | Multicopy by kanamycine (#13) |
| Lane 7: | Multicopy by kanamycine (#14) |
| Lane 8: | Multicopy by galactose (#15) |
| Lane 9: | Multicopy by galactose (#17) |
| Lane 10: | Multicopy by kanamycine (#19) |
| Lane 11: | Multicopy by galactose (#21) |
| Lane 12: | Multicopy by galactose (#25) |
| Lane 13: | Multicopy by galactose (#27) |

10028
SEQUENCE LISTING

<110> Novo Nordisk A/S

<120> Method for Increasing Gene Copy Number

<130> 10028.204-WO

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 6405

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pMOL1748

<400> 1

```

ctaaatcggg agaagcccaa acgttccacg atgcgatttg tgcccttacc gtagaagagc 60
tggttgaata tgcaggcaaa tggcgttaata ttcgtgtgca aggaccgaca acatttctac 120
catccttgac tgtacaggta gcaatggcag gtgccatggt gattggtctg catcatcgca 180
tctgttatac gacgagcgct tcggtcctaa ctgaagcagt taagcaatca gatcttctct 240
caggttatga ccatctgtgc cagttcgtaa tgtctggtca actttccgac tctgagaaac 300
ttctggaatc gctagagaat ttctggaatg ggattcagga gtggacagaa cgacacggat 360
atatagtga tgtgtcaaaa cgcataccat ttgaaacgat gacctctaata aattgttaata 420
catgttggag ctccagtga gccaagcgaa cacttgattt tttaattttc tatcttttat 480
aggtcattag agtatactta tttgtcctat aaactattta gcagcataat agatttattg 540
aataggatcat ttaagttgag catattagag gaggaataatc ttggagaaat atttgaagaa 600
cccgagaatg gaggccttct caattgagaa ggcctttttt aaagaacaag ggtgcctaaa 660
caggcaccct tgttagctgt tatttgattt tcacaataac atcattactg aatttttagtt 720
tccaagtgcc ttttgcatga gtttccttgt caacttcaaa tgcttttaca cctgttactt 780
taatattagg atttagatca ctcaaaattt tagagttatc aacttttgtc tcagttgcat 840
agtttacaga agcatcaata tcagaatcat aagaagtacc atcagcatca actaatttaa 900
cagttggaat tgaaaaagag ctaatcggct ttttagatac gtttttaatt gtatattgaa 960
cagctacaat tgtacctcag cggcgacgag ggtcgacgag gccgcaacca tttgatcaaa 1020
gcttgcagtc ctgcaggctc attcacaaaa aataggcaca cgaaaaacaa gtttaaggat 1080
gcagtttatg catcccttaa cttacttatt aaataattta tagctattga aaagagataa 1140
gaattgttca aagctaatat tgtttaaatc gtcaattcct gcatgtttta aggaattggt 1200
aaattgattt tttgtaaata ttttcttgta ttctttgtta acccatttca taacgaaata 1260
attatacttt tgtttatctt tgtgtgatat tcttgatttt tttctactta atctgataag 1320
tgagctattc acttttaggt taggatgaaa atattctctt ggaaccatac ttaatataga 1380
aatatcaact tctgccatta aaagtaatgc caatgagcgt tttgtattta ataactttt 1440
agcaaacccg tattccacga ttaaataaat ctcatagct atactatcaa aaacaatttt 1500
gcgtattata tccgtactta tgttataagg tatattacca tatattttat aggattggtt 1560
tttaggaaat ttaaactgca atatatcctt gtttaaaact tggaaattat cgtgatcaac 1620
aagtttattt tctgtagttt tgcataaatt atgggtctatt tcaatggcag ttacgaaatt 1680
acacctcttt actaattcaa gggtaaaatg gccttttcct gagccgattt caaagatatt 1740
atcatgttca ttaaatctta tatttgcatt tattttatct atattatggt ttgaagtaat 1800
aaagttttga ctgtgtttta tatttttctc gtccattata accctcttta atttggttat 1860
atgaattttg cttattaacg attcattata accacttatt ttttggttgg ttgataatga 1920
actgtgctga ttacaaaaat actaaaaatg cccatatttt ttcctcctta taaaattagt 1980
ataattatag caccagctct gataaatatg aacatgatga gtgatcgta aatttatact 2040
gcaatcggat gcgattattg aataaaagat atgagagatt tatctaattt cttttttctt 2100
gtaaaaaag aaagttctta aaggttttat agttttggtc gtagagcaca cggtttaacg 2160
acttaattac gaagtaata agtctagtgt gttagacttt atgaaatcta tatacgttta 2220
tatattatta ttatccggag gtgtagcatg tctcattcaa ttttgagggt tgccagagtt 2280
aaaggatcaa gtaatacaaa cgggatacaa agacataatc aaagagagaa taaaaactat 2340
aataataaag acataaatca tgaggaaaca tataaaaatt atgatttgat taacgcacaa 2400

```

10028

aatataaagt	ataaagataa	aattgatgaa	acgattgatg	agaattattc	agggaaacgt	2460
aaaattcggg	cagatgcaat	tgcacatgtg	gacggactgg	ttacaagtga	taaagatttc	2520
tttgatgatt	taagcggaga	agaaatagaa	cgatttttta	aagatagctt	ggagtttcta	2580
gaaaatgaat	acggtaagga	aaatatgctg	tatgcgactg	tccatctgga	tgaaagagtc	2640
ccacatatgc	acttttggtt	tgtcccttta	acagaggacg	ggagattgtc	tgcaaaagaa	2700
cagttaggca	acaagaaaga	ctttactcaa	ttacaagata	gatttaatga	gtatgtgaat	2760
gagaaagggt	atgaacttga	aagaggcacg	tccaaagagg	ttacagaacg	agaacataaa	2820
gcgatggatc	agtaacaaga	agatactgta	tttcataaac	aggaactgca	agaagttaag	2880
gatgagttac	agaaggcaaa	taagcagtta	cagagtggaa	tagagcatat	gaggtctacg	2940
aaaccctttg	attatgaaaa	tgagcgtaca	ggtttgttct	ctggacgtga	agagactggg	3000
agaaagatat	taactgctga	tgaatttgaa	cgctgcaag	aaacaatctc	ttctgcagaa	3060
cggattgttg	atgattacga	aaatattaag	agcacagact	attacacaga	aaatcaagaa	3120
ttaaaaaaac	gtagagagag	tttgaaagaa	gtagtgaaata	catggaaaga	gggggtatcac	3180
gaaaaaagta	aagagggttaa	taaattaaag	cgagagaatg	atagtttgaa	tgagcagttg	3240
aatgtatcag	agaaatttca	agctagtaca	gtgactttat	atcgtgctgc	gagggcgaaat	3300
ttccctgggt	ttgagaaagg	gtttaatagg	cttaaagaga	aattctttaa	tgattccaaa	3360
tttgagcgtg	tgggacaggt	tatggatggt	gtacaggata	atgtccagaa	ggtcgataga	3420
aagcgtgaga	aacagcgtac	agacgattta	gagatgtaga	ggtactttta	tgccgagaaa	3480
actttttgcg	tgtgacagtc	cttaaaatat	acttagagcg	taagcgaaag	tagtagcgac	3540
agctattaac	tttcggtttc	aaagctctag	gattttttaa	ggacgcagcg	catcacacgc	3600
aaaaaggaaa	ttggaataaa	tgcgaaattt	gagatgttaa	ttaaagacct	ttttgaggtc	3660
tttttttctt	agattttttg	ggttattttg	gggagaaaac	ataggggggt	actacgacct	3720
ccccctagg	tgtccattgt	ccattgtoca	aacaaataaa	taaatattgg	gtttttaatg	3780
ttaaaagggt	gttttttatg	ttaaagtga	aaaaacagat	gttgggaggt	acagtgatgg	3840
ttgtagatag	aaaagaagag	aaaaaagttg	ctgttacttt	aagacttaca	acagaagaaa	3900
atgagatatt	aaatagaatc	aaagaaaaat	ataatattag	caaatcagat	gcaaccggta	3960
ttctaataaa	aaaatatgca	aaggaggaaat	acggtgcatt	ttaaacaaaa	aaagatagac	4020
agcactggca	tgctgcctat	ctatgactaa	attttgttaa	gtgtattagc	accgttatta	4080
tatcatgagc	gaaaatgtaa	taaaagaac	tgaaaacaag	aaaaattcaa	gaggacgtaa	4140
ttggacattt	gttttatatc	cagaatcagc	aaaagccgag	tggttagagt	atttaaaaga	4200
gttacacatt	caattttgtg	tgtctccatt	acatgatagg	gatactgata	cagaaggtag	4260
gatgaaaaaa	gagcattatc	atattctagt	gatgtatgag	ggtaataaat	cttatgaaca	4320
gataaaaaata	attacagaag	aattgaatgc	gactattccg	cagattgcag	gaagtgtgaa	4380
aggtcttgtg	agatatatgc	ttcacatgga	cgatccta	aaatttaaat	atcaaaaaga	4440
agatatgata	gtttatggcg	gtgtagatgt	tgatgaatta	ttaaagaaaa	caacaacaga	4500
tagatataaa	ttaattaaag	aaatgattga	gtttattgat	gaacaaggaa	tcgtagaatt	4560
taagagttta	atggattatg	caatgaagtt	taaaattgat	gattggttcc	cgcttttatg	4620
tgataactcg	gcgtatgta	ttcaagaata	tataaaatca	aatcgggata	aatctgaccg	4680
atagattttg	aatttaggtg	tcacaagaca	ctcttttttc	gcaccagcga	aaactggttt	4740
aagccgactg	cgcaaaagac	ataatcgact	ctagaggatc	cttttagtcc	agctgatttc	4800
actttttgca	ttctacaaac	tgcataactc	atatgtaaat	cgctcctttt	taggtggcac	4860
aaatgtgagg	cattttcgtc	ctttccggca	accacttcca	agtaaagtat	aacacactat	4920
acttttatatt	cataaagtgt	gtgctctgcg	aggtgtcgg	cagtgccgac	caaaaaccata	4980
aaacctttta	gacctttctt	ttttttacga	gaaaaaaaga	acaaaaaaac	ctgccctctg	5040
ccacctcagc	aaaggggggt	tttgcctctg	tgctcgttta	aaaatcagca	agggacaggt	5100
agtatttttt	gagaagatca	ctcaaaaaat	ctccaccttt	aaacccttgc	caatttttat	5160
tttgcctggt	ttgtctagct	taccgaaagc	cagactcagc	aagaataaaa	tttttattgt	5220
ctttcggttt	tctagtgtaa	cggacaaaaac	cactcaaaat	aaaaaagata	caagagaggt	5280
ctctcgtatc	ttttattcag	caatcgcgcc	cgattgtcga	acagattaat	aatgagccgc	5340
gggtgaggaa	agacaggact	tgatgataca	agggcaaaac	agctttgctt	caccgcttgc	5400
gggaagcaac	gatccaaagg	tgattcacca	gtattgcggg	ccgacaccgc	ctgacaagga	5460
tcatgcgtat	acattgacgg	tctatgcttt	agatgctgag	ctgaatcttc	agccgggctt	5520
ttacttgaat	gagctctatc	aagaaatgaa	agagcacatt	cttgctgaaa	cctctatcga	5580
attgctggca	agggtttaag	ggttctgaat	tctgatcaaa	tggttcagtg	agagcgaagc	5700
cttaaaaaatg	gatgtggacc	ttctatcttt	tataggtcat	tagagtatac	ttatttgtcc	5760
gaacacttga	ttttttaatt	aatagattta	ttgaataggt	catttaagtt	gagcatatta	5820
tataaactat	ttagcagcat	aatatttgaa	gaaccogaac	gcgtgagtag	ttcaacaaac	5880
gaggaggaaa	atcttggaga	agatgctata	attgttatta	aaaggattga	aggatgctta	5940
gggccagttt	gttgaagatt	ctgaataaga	acggtgctct	ccaaatattc	ttatttagaa	6000
ggaagacgag	ttattaatag	gaaaagggaa	tgagaatagt	gaatggacca	ataataatga	6060
aagcaaatct	aaaattatct	attgttcatg	aaattaagga	acgaatattg	gataaatatg	6120
ctagagaaga	aagaatgaag	ggtgtttatg	gctctcttgg	tcgtcagact	gatgggacct	6180
gggatgatgt	taaggctatt	tgtgtcatgt	caacagagga	agcagagttc	agccatgaat	6240
attcggatat	tgagatgatg					

10028

ggacaaccgg tgagtggaag gtggaagtga attttgatag cgaagagatt ctactagatt 6300
 atgcatctca ggtggaatca gattggccgc ttacacatgg tcaatttttc tctattttgc 6360
 cgatttatga ttcaggtgga tacttagaga aagtgtatca aactg 6405

<210> 2

<211> 5943

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pMOL1807

<400> 2

gatccatctg aaggtcgata cggggatgaa cagacttggg gtaaaaacag aggaagaagt 60
 tcagaacgtg atggcaattc ttgaccgcaa ccctcgttta aagtgcagg ggggtatttac 120
 ccatttttgc acagcggatg aaaaagaaag aggtctattc ttaatgcagt ttgagcgctt 180
 taaagagctg attgctccgc tgccgttaaa gaatctaag gtccactgcg cgaacagcgc 240
 cgctggactc cggctgaaaa aaggcttttt taatgcagtc agattcggca tcggcatgta 300
 tggccttgcg ccgtctgctg acatgtcgga cgagataccg ttccagctgc gtccggcatt 360
 taccctgcat tcgacactgt cacatgtcaa actgatcaga aaaggcgaga gcgtcagcta 420
 cggagccgag tacacagcgg aaaaagacac atggatcggg acggtgcctg taggctatgc 480
 ggacggctgg ctccgaaaat tgaaagggac cgacatcctt gtgaagggaa aacgcctgaa 540
 aattgcggcg cgaatttgca tggaccaatt tatggtggag ctggatcagg aatatccgcc 600
 gggcacaataa gtcacattaa taggccggca gggggatgaa tatatttcca tggatgagat 660
 tgcaggaagg ctcgaaacca ttaactatga ggtggcctgt acaataagtt cccgtgttcc 720
 ccgtatgttt ttggaaaatg ggagtataat ggaagtaaga aatcctttat tgcaggtaaa 780
 tataagcaat taacttacct aaatggagaa ttcataaaac agctttgcgt cgacgatgaa 840
 gatggatttt ctattattgc aatgtggaat tgggaacgga aaaattattt tattaagag 900
 tagttcaaca aacgggccag tttgttgaag attagatgct ataattgtta ttaaaaggat 960
 tgaaggatgc ttaggaagac gaggttatga tagctgaata agaacggtgc tctccaaata 1020
 ttcttattta gaaaagcaaa tctaaaatta tctgaaaagg gaatgagaat agtgaatgga 1080
 ccaataataa tgactagaga agaagaatg aagattgttc atgaaattaa ggaacgaata 1140
 ttggataaat atggggatga tgtaaggct attggtgttt atggctctct tggctgctcag 1200
 actgatgggc cctattcgga tattgagatg atgtgtgtca tgtcaacaga ggaagcagag 1260
 ttccagcatg aatggacaac cggtagtggt aaggtggaag tgaattttga tagcgaagag 1320
 attctactag attatgcata tcaggtggaa tcagattggc cgcttacaca tggatcaatt 1380
 ttctctattt tgccgattta tgattcaggt ggatacttag agaaagtgtg tcaaaactgct 1440
 aaatcggtag aagcccaaac gttccacgat gcgatttgtg cccttatcgt agaagagctg 1500
 tttgataatg caggcaaatg cgttaatatg gactgtgcaa gaccgacaac atttctacca 1560
 tccttgactg tacaggtagc aatggcaggt gccatgttga ttggtctgca tcatcgcatc 1620
 tggtatacga cgagcgcttc ggtcttaact gaagcagtta agcaatcaga tcttccttca 1680
 ggttatgacc atctgtgcca gttcgtaatg tctggtcaac tttccgactc tgagaaactt 1740
 ctggaatcgc tagagaattt ctggaatggg attcaggagt ggacagaacg acacggatat 1800
 atagtggatg tgtcaaaaac cataccattt tgaacgatga cctctaataa ttgttaatac 1860
 tggtggttac gtatttatta acttctccta gtattagtaa ttatcatggc tgtcatggcg 1920
 cattaacgga ataaaggggtg tgcttaaatc gggccatttt cgctaataag aaaaaggatt 1980
 aattatgagc gaattgaatt aataataagg taatagattt acattagaaa atgaaagggg 2040
 attttgcggc cgcaacctc gagatctctt agatttttgg ggttatttag gggagaaaac 2100
 ataggggggt actacgacct cccccctagg tgtccattgt ccattgtcca acaaaataaa 2160
 taaatattgg gtttttaatt ttaaaagggt gttttttatg ttaaaagtga aaaaacagat 2220
 gttgggaggt acagtgatgg ttgtagatag aaaagaagag aaaaaagttg ctgttacttt 2280
 aagacttaca acagaagaaa atgagatatt aatatggagt tcgagctcat tattaatctg 2340
 ttcagcaatc gggcgcgatt gctgaataaa agatacgaga gacctctctt gtatcttttt 2400
 tatttttgagt ggtttttgtc gtacactag aaaaaccgaaa gacaataaaa attttattct 2460
 tgctgagctc ggctttcggg aagctagaca aaacggacaa aataaaaaatt ggcaagggtt 2520
 taaaggtgga gattttttga gtgatcttct caaaaaatc tacctgtccc ttgctgattt 2580
 ttaaaccgagc acgagagcaa aacccccctt tgctgaggtg gcagagggca ggtttttttg 2640
 tttctttttt ctcgtaaaaa aaagaaagggt cttaaagggt ttatgggttt ggtcggcact 2700
 gccgacagcc tcgcagagca cacactttat gaaatataag tatagtgtgt tatactttac 2760
 ttggaagtgg ttgccggaat gagcgaaaat gcctcacatt tgtgccacct aaaaaggagc 2820
 gatttacata tgagttatgc agttttaga atgcaaaaag tgaaatcagc tggactaaaa 2880
 ggcagagctc ggtaccggg agctctatca attggttaact gtatctcagc ttgaagaagt 2940
 gaagaagcag agaggctatt gaataaatga gtagaagcgc catatcggcg cttttctttt 3000

10028

```

ggacaaccgg  tgagtggaag  gtggaagtga  attttgatag  cgaagagatt  ctactagatt  6300
atgcatctca  ggtggaatca  gattggccgc  ttacacatgg  tcaatttttc  tctattttgc  6360
cgatttatga  ttcaggtgga  tacttagaga  aagtgtatca  aactg       6405

```

<210> 2

<211> 5943

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pMOL1807

<400> 2

```

gatccatctg  aaggtcgata  cggggatgaa  cagacttggg  gtaaaaacag  aggaagaagt  60
tcagaacgtg  atggcaattc  ttgaccgcaa  ccctcgttta  aagtgc aaag  gggatatttac  120
ccattttgcg  acagcggatg  aaaaagaaag  aggtattttc  ttaatgcagt  ttgagcgctt  180
taaagagctg  attgctccgc  tgccgttaaa  gaatctaata  gtccactgcy  cgaacagcgc  240
cgctggactc  cgggtgaaaa  aaggcttttt  taatgcagtc  agattcggca  tcggcatgta  300
tggccttcgc  ccgtctgctg  acatgtcggg  cgagataccg  tttcagctgc  gtccggcatt  360
taccctgcat  tcgacactgt  cacatgtcaa  actgatcaga  aaaggcgaga  gcgtcagcta  420
cggagccgag  tacacagcgg  aaaaagacac  atggatcggg  acgggtgctg  taggctatgc  480
ggacggctgg  ctccgaaaat  tgaaggggac  cgacatcctt  gtgaagggaa  aacgcctgaa  540
aattgcgggc  cgaatttgca  tggaccaatt  tatggtggag  ctggatcagg  aatatccgcc  600
gggcacaaaa  gtcacattaa  taggcgggca  gggggatgaa  tatatttcca  tggatgagat  660
tgcaggaaag  ctcgaaacca  ttaactatga  ggtggcctgt  acaataagtt  cccgtgttcc  720
ccgtatgttt  ttggaaaatg  ggagtataat  ggaagtaaga  aatcctttat  tgcaggtaaa  780
tataagcaat  taacttacct  aaatggagaa  ttcataaaac  agctttgcgt  cgacgatgaa  840
gatggatttt  ctattattgc  aatgtggaat  tgggaacgga  aaaattattt  tattaagag  900
tagttcaaca  aacgggccag  tttgttgaag  attagatgct  ataattgtta  ttaaaaggat  960
tgaaggatgc  ttagggaagc  gagtatttaa  tagctgaata  agaacggtgc  tctccaaata  1020
ttcttattta  gaaaagcaaa  tctaaaatta  tctgaaaagg  gaatgagaat  agtgaatgga  1080
ccaataataa  tgactagaga  agaaagaatg  aagattgttc  atgaaattaa  ggaacgaata  1140
ttggataaat  atggggatga  tgtaaggct  attggtgttt  atggctctct  tggctcgtag  1200
actgagggg  cctattcgga  tattgagatg  atgtgtgtca  tgtcaacaga  ggaagcagag  1260
ttcagccatg  aatgggacaac  cggtagtgag  aagggtggaag  tgaattttga  tagcgaagag  1320
attctactag  attatgcata  tcaggtggaa  tcagattggc  cgcttacaca  tggatcaatt  1380
ttctctattt  tgccgattta  tgattcaggt  ggatacttag  agaaagtgt  tcaaaactgt  1440
aaatcggtag  aagcccaaac  gttccacgat  gcgatttgtg  cccttatcgt  agaagagctg  1500
tttgaatatg  taggcaaatg  gcgtaatat  cgtgtgcaag  gaccgacaac  atttctacca  1560
tccttgactg  tacaggtagc  aatggcaggt  gccatgttga  ttggtctgca  tcatcgcatc  1620
tggtatacga  cgagcgcttc  ggtcttaact  gaagcagtta  agcaatcaga  tcttccttca  1680
ggttatgacc  atctgtgcca  gttcgtaatg  totggtcaac  tttccgactc  tgagaaactt  1740
ctggaatcgc  tagagaattt  ctggaatggg  attcaggagt  ggacagaacg  acacggatat  1800
atagtggatg  tgtcaaacg  cataccattt  tgaacgatga  cctctaataa  ttgttaatac  1860
tggtggttac  gtatttatta  acttctccta  gtattagtaa  ttatcatggc  tgtcatggcg  1920
cattaacgga  ataaagggg  tgcttaaatc  gggccatttt  cgctaataag  aaaaaggatt  1980
aattatgagc  gaattgaatt  aataataagg  taatagattt  acattagaaa  atgaaagggg  2040
atthtcgggc  cgccaacctc  gagatctctt  agatttttgg  ggttatttag  gggagaaaaa  2100
ataggggggt  actacgacct  cccccctagg  tgtccattgt  ccattgtcca  aacaaataaa  2160
taaataattg  gtttttaatg  ttaaaagggt  gttttttatg  ttaaagtga  aaaaacagat  2220
ggtgggaggt  acagtgatgg  ttgtagatag  aaaagaagag  aaaaaagttg  ctgttacttt  2280
aagacttaca  acagaagaaa  atgagatatt  aaataggaat  tcgagctcat  tattaatctg  2340
ttcagcaatc  gggcgcgatt  gctgaataaa  agatacgaga  gacctctctt  gtatcttttt  2400
tattttgagt  ggttttgtcc  gttacactag  aaaaccgaaa  gacaataaaa  attttattct  2460
tgctgagctc  ggttttcggg  aagctagaca  aaacgggaca  aataaaaaat  ggcaagggtt  2520
taaagggtga  gattttttga  gtgatcttct  caaaaaatac  tacctgtccc  ttgctgattt  2580
ttaaacgagc  acgagagcaa  aacccccctt  tgctgaggtg  gcagagggca  ggtttttttg  2640
tttctttttt  ctctgtaaaa  aaagaaagg  cttaaagggt  ttatggtttt  ggtcggcact  2700
gccgacagcc  tcgagagcaa  cacactttat  gaataaaaag  tatagtgtgt  tatactttac  2760
ttggaagtgg  ttgcccggaa  gagcgaaaat  gcctcacatt  tgtgccacct  aaaaaggagc  2820
gatttacata  tgagttatgc  agttttaga  atgcaaaaag  tgaaatcagc  tggactaaaa  2880
ggcagagctc  ggtaccggg  agctctatca  attggtaact  gtatctcagc  ttgaagaagt  2940
gaagaagcag  agaggctatt  gaataaatga  gtagaagcgc  catatcggcg  cttttctttt  3000

```

10028

```

ggaagaaaat atagggaaaa tggacttctg taaaaattcg gaatatattat acaatatcat 3060
atgttacaca ttgaaagggg aggagaatca tgaacaaca aaaacggctt tacgcccgat 3120
tgctgacgct gttatttgcg ctcactctct tgctgcctca ttctgcagcc gcggcacacc 3180
ataatgggtac gaacggcaca atgatgcagt actttgaatg gtatctacca aatgacggaa 3240
accattggaa tagattaagg tctgatgcaa gtaacctaaa agataaaggg atctcagcg 3300
tttgattccc tcctgcatgg aagggtgcct ctcaaaatga tgtggggtat ggtgcttatg 3360
atctgtatga tttaggagaa ttcaatcaaa aaggaacatc tcgtacaaaa tatggaacgc 3420
gcaatcagtt acaagctgcg gttaacgcct tgaagagtaa tggaaattcaa gtgtatggcg 3480
atgttgtaat gaatcataaa gggggagcag acgctaccga aatggttagg gcagttgaag 3540
taaaccggaa taatagaaat caagaagtgt ccggtgaata tacaattgag gcttggacaa 3600
agtttgactt tccaggacga ggtaatactc attcaaaactt caaatggaga tggatcact 3660
ttgatggagt agattgggat cagtacagta agctgaacaa tcgaatttat aaatttagag 3720
gtgatggaaa aggggtggat tgggaagtgc atacagaaaa cggtaactat gattacctaa 3780
tgtatgcaga tattgacatg gatcaccag aggtagtga tgagctaaga aattgggggtg 3840
tttggtatac gaatacatta ggccttgatg gttttagaat agatgcagta aaacatataa 3900
aatacagctt tactcgtgat tggattaatc atgttagaag tgcaactggc aaaaatatgt 3960
ttgcggttgc ggaatttttg aaaaatgatt taggtgctat tgaaaactat ttaacaaaa 4020
caaactggaa ccattcagtc tttgatgttc cgctgcacta taacctctat aatgctcaa 4080
aaagcggagg gaattatgat atgaggcaaa tatttaatgg tacagtcgtg caaagacatc 4140
caatgcatgc tgttacattt gttgataatc atgattcgca acctgaagaa gcttttagag 4200
cttttgttga agaatggttc aaaccattag cgtatgcttt gacattaaca cgtgaacaag 4260
gctacccctc tgtattttat ggagattatt atggcattcc aacgcatggt gtaccagcga 4320
tgaaatcgaa aattgacccg attctagaag cgcgtcaaaa gtatgcatat ggaagacaaa 4380
atgactactt agaccatcat aatcatcctg gttggacag tgaagggaat acagcacacc 4440
ccaactccgg tttagctact atcatgtccg atggggcagg aggaaataag tggatgtttg 4500
ttgggcgtaa taaagctggt caagtttggg ccgatatcac tggaaatcgt gcaggtactg 4560
ttacgattaa tgctgatgga tggggtaatt tttctgtaaa tggaggatca gtttctattt 4620
gggtaacaaa ataagtcgac ggcccagccg gccgagctcg gatagaagag cagagaagac 4680
ggatttcctg aaggaaatcc gtttttttat tttgcccgtc ttataaattt ctttgattac 4740
attttataat taattttaac aaagtgtcat aagcccgtat gaattattgt gaagcttatc 4800
gataacaggt catttttttag gaggttttac atcatggcaa tacttgttac tggcggtgcc 4860
ggttacattg gcagccacac atgtgttgaa ctattgaaca gcggctacga gattgttgtt 4920
cttgataatc tgtccaacag ttcagctgaa gcgctgaacc gtgtcaagga gattacagga 4980
aaagatttaa cgttctacga agcggattta ttggaccggg aagcggtaga ttccgttttt 5040
gctgaaaatg aaatcgaagc tgtgattcat tttgcagggt taaaagcagt cggcgaatct 5100
gtggcgattc ccctcaaata ttatcataac aatttgacag gaacgtttat tttatgcgag 5160
gccatggaga aatacggcgt caagaaaatc gtattcagtt catctgcgac agtatacggc 5220
gttccggaaa catcgccgat tacggaagac tttccattag gcgcgacaaa tccttatggg 5280
tagactcta caggagccga acaaatattg cgtgatttgc atacagccga caatgagtgg 5340
agcgttgcg tgcctcgtaa ctttaaccgg ttcggcgcg atccaaagcgg acggatcggg 5400
gaagaccgga acggaatccc aaataacctt atgccgtatg tggcacaggt agcagtcggg 5460
aagctcgagc aattaagcgt attcggaat gactatccga caaaagacgg gacaggcgta 5520
cgcgattata ttcacgtcgt tgatctcgca gaaggccacg tcaaggcgct ggaaaaagta 5580
ttgaactcta caggagccga ttggaacag gcacaggcta cagcgtgctg 5640
gaaatggtea aagcctttga aaaagtgtca gggaaaagagg ttccataccg ttttgcggac 5700
cgccgtccgg gagacatcgc cacatgcttt gcagatcctg cgaaagccaa gcgagaacta 5760
ggctgggaag cgaacgcggg ccttgaggaa atgtgtgctg attcctggag atggcagctc 5820
tctaattgtg atgggtataa gagtgcgga taagaatgga ggccttctca attgagaagg 5880
ccttttttaa agaacaaggg tgcctaaaca ggcacccttg ttagctgtta tttgattttc 5940
acg
5943

```

<210> 3

<211> 5793

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pMOL1809

<400> 3

```

gatccatctg aaggctcgata cggggatgaa cagacttggt gtaaaaacag aggaagaagt 60
tcagaacgtg atggcaattc ttgaccgcaa ccctcgttta aagtgcaaag gggatatttac 120
ccattttgcg acagcggatg aaaaagaaag aggtatattc ttaatgcagt ttgagcgctt 180

```

10028

taaagagctg	attgctccgc	tgccgttaaa	gaatctaag	gtccactgcg	ogaacagcgc	240
cgctggactc	cggctgaaaa	aaggcttttt	taatgcagtc	agattcggca	tcggcatgta	300
tggccttcgc	cgcgtcgcgtg	acatgtcggg	cgagataccg	tttcagctgc	gtccggcatt	360
taccctgcat	tcgacactgt	cacatgtcaa	actgatcaga	aaaggcgaga	gcgtcagcta	420
cggagccgag	tacacagcgg	aaaaagacac	atggatcggg	acggtgcctg	taggctatgc	480
ggacggctgg	ctccgaaaaat	tgaaagggac	cgacatcctt	gtgaagggaa	aacgcctgaa	540
aattgccggc	cgaatttgca	tggaccaatt	tatggtggag	ctggatcagg	aatatccgcc	600
gggcacaaaa	gtcacattaa	taggccggca	gggggatgaa	tatatttcca	tggatgagat	660
tgcaggaagg	ctcgaacca	ttaactatga	ggtggcctgt	acaataagtt	cccgtgttcc	720
cogtatgttt	ttggaaaaatg	ggagtataat	ggaagtaaga	aatcctttat	tgcaggtaaa	780
tataagcaat	taacttacct	aaatggagaa	ttcataaaac	agctttgcgt	cgacgatgaa	840
gatggatttt	ctattattgc	aatgtggaat	tgggaacgga	aaaattattt	tattaaagag	900
tagttcaaca	aacgggccag	tttgttgaag	attagatgct	ataattgtta	ttaaaaggat	960
tgaaggatgc	ttaggaagac	gagttattaa	tagctgaata	agaacgggtg	tctccaaata	1020
ttcttattta	gaaaagcaaa	tctaaaaatta	tctgaaaagg	gaatgagaat	agtgaatgga	1080
ccaataataa	tgactagaga	agaaagaatg	aagattgttc	atgaaattaa	ggaacgaaat	1140
ttggataaat	atggggatga	tgtaaggct	attggtgttt	atggctctct	tggtcgtcag	1200
actgatgggc	cctattcggg	tattgagatg	atgtgtgtca	tgtcaacaga	ggaagcagag	1260
ttcagccatg	aatggacaac	cggtagtggt	aaggtggaag	tgaattttga	tagcgaagag	1320
attctactag	attatgcattc	tcaggtggaa	tcagattggc	cgcttacaca	tggtcaattt	1380
ttctctattt	tgccgattta	tgattcaggt	ggatacttag	agaaagtgtg	tcaaaactgct	1440
aaatcggtag	aagcccaaac	gttccacgat	gogatttgtg	cccttatcgt	agaagagctg	1500
tttgaatatg	caggcgaatg	gcgtaatatt	cgtgtgcaag	gaccgacaac	atttctacca	1560
tccttgactg	tcaggttagc	aatggcaggt	gccatgttga	ttggtctgca	tcacgcacgc	1620
tggtatcgca	cgagcgcttc	ggtcttaact	gaagcagtta	agcaatcaga	tcttccttca	1680
ggttatgacc	atctgtgcc	gttcgtaatg	tctggtcaac	tttcgactc	tgagaaactt	1740
ctggaatcgc	tagagaattt	ctggaatggg	attcaggagt	ggacagaacg	acacggatat	1800
atagtggatg	tgtcaaaacg	cataccattt	tgaacgatga	cctctaataa	ttgttaatca	1860
tgttggttac	gtatttatta	acttctccta	gtattagtaa	ttatcatggc	tgcatggcgc	1920
cattaacgga	ataaagggtg	tgcttaaatc	gggccatttt	cgctaataag	aaaaaggatt	1980
aattatgagc	gaattgaatt	aataataagg	taatagattt	acattagaaa	atgaaagggg	2040
attttgcggc	cgccaacctc	gagatctctt	agatttttgg	ggttatttag	gggagaaaaa	2100
ataggggggt	actacgacct	cccccttagg	tgtccattgt	ccattgtcca	aacaaataaa	2160
taaatattgg	gtttttaatg	ttaaaagggt	gttttttatg	ttaaagtga	aaaaacagat	2220
gttgggaggt	acagtgatgg	ttgtagatag	aaaagaagag	aaaaaagtgt	ctgttacttt	2280
aagacttaca	acagagaaa	atgagatatt	aaataggaat	tcgagctcat	tattaatctg	2340
ttcagcaatc	gggoccgatt	gctgaataaa	agatacgaga	gacctctctt	gtatcttttt	2400
tattttgagt	ggttttgtcc	gttacactag	aaaaccgaaa	gacaataaaa	attttattct	2460
tgtcagttct	ggctttcggg	aagctagaca	aaacggacaa	aataaaaaat	ggcaagggtt	2520
taaaagtgga	gattttttga	gtgatcttct	caaaaaatac	tacctgtccc	ttgctgattt	2580
ttaaaccgagc	acgagagcaa	aacccccctt	tgctgaggtg	gcagagggca	ggtttttttg	2640
tttctttttt	ctcgtaaaaa	aaagaaagggt	cttaaagggtt	ttatggtttt	ggtcggcact	2700
gccgacagcc	tcgcagagca	cacactttat	gaatataaag	tatagtgtgt	tatactttac	2760
ttggaagtgg	ttgccggaaa	gagcgaaaat	gcctcacatt	tgtgccacct	aaaaaggagc	2820
gattttacata	tgagttatgc	agtttgtaga	tgcaaaaaag	tgaaatcagc	tggactaaaa	2880
ggcagagctc	ggtagccggg	agctctatca	attggttaact	gtatctcagc	ttgaagaagt	2940
gaagaagcag	agaggctatt	gaataaatga	gtagaagcgc	catatcggcg	cttttctttt	3000
ggaagaaaat	atagggaaaa	tggtaactgt	taaaaattcg	gaatatttat	acaatatcat	3060
atgttacaca	ttgaaagggg	aggagaatca	tgaacaaca	aaaacggctt	tacgcccgat	3120
tgtcagcgtc	gttatttgcg	ctcatcttct	tgctgcctca	ttctgcagcc	gcggcacacc	3180
ataatggtac	gaacggcaca	atgatgcagt	actttgaatg	gtatctacca	aatgacggaa	3240
accattggaa	tagattaagg	tctgatgcaa	gtaacctaaa	agataaaggg	atctcagcgg	3300
tttggtatcc	tcctgcattg	aagggtgcct	ctcaaaatga	tgtggggtat	gggtgcttat	3360
atctgtatga	tttaggagaa	ttcaatcaaa	aaggaacctat	tcgtacaaaa	tatggaacgc	3420
gcaatcaggt	acaagctgcg	gttaacgcct	tgaaaagttaa	tggaaattcaa	gtgtatggcg	3480
atgttgaat	gaatcataaa	gggggagcag	acgctaccga	aatgggttagg	gcagttgaag	3540
taaacccgaa	taatagaaat	caagaagtgt	ccggtgaata	tacaattgag	gcttggacaa	3600
agtttgactt	tccaggacga	ggtaatactc	attcaaaact	caaatggaga	tggtatcact	3660
ttgatggagt	agattgggat	cagtcacgta	agctgaacaa	tcgaatttat	aaatttagag	3720
gtgatggaaa	agggtgggat	tgggaagtgc	atcacagaaa	cggtaactat	gattacctaa	3780
tgtatgcaga	tattgacatg	gatcaccag	aggtagtgaa	tgagctaaga	aattgggggtg	3840
tttggtatc	gaatacatta	ggccttgatg	gttttagaat	agatgcagta	aaacatatata	3900
aatacagctt	tactcgtgat	tggattaatc	atgttagaag	tgcaactggc	aaaaatatgt	3960
ttgcggttgc	ggaatttttg	aaaaatgatt	taggtgctat	tgaaaactat	ttaaacaaaa	4020

WO 01/90393

10028

```

caaaactggaa ccattcagtc tttgatgttc cgctgcacta taacctctat aatgcttcaa 4080
aaagcggagg gaattatgat atgaggcaaa tattaatgg tacagtcgtg caaagacatc 4140
caatgcagtc tgttacattt gttgataatc atgattcgca acctgaagaa gctttagagt 4200
cttttgttga agaattggtc aaaccattag cgtatgcttt gacattaaca cgtgaacaag 4260
gctacccttc tgtattttat ggagattatt atggcattcc aacgcattgg gtaccagcga 4320
tgaaatcgaa aattgacccg attctagaag cgcgtcaaaa gtatgcatat ggaagacaaa 4380
atgactactt agaccatcat aatatcatcg gttggacacg tgaagggaat acagcacacc 4440
ccaactccgg ttttagctact atcatgtccg atggggcagg aggaaataag tggatgtttg 4500
ttgggcgtaa taaagctggt caagtttggg cggatatcac tggaaatcgt gcagggtactg 4560
ttacgattaa tgctgatgga tggggttaatt tttctgtaaa tggaggatca gtttctattt 4620
gggtaaacaa ataagtcgac ggcccagccg gccaacagggt gcagccacac atgtgttgaa 4740
atcatggcaa tacttgttac tggcgggtgcc gggttacattg gcagccacac atgtgttgaa 4800
ctattgaaca gcggctacga gattgttgtt cttgataatc tgtccaacag ttcagctgaa 4860
gcgctgaacc gtgtcaagga gattacagga aaagatttaa cgttctacga agcggattta 4920
ttggaccggg aagcggtaga ttccggtttt gctgaaaatg aaatcgaagc tgtgattcat 4980
tttgacgggt taaaagcagt cggcgaatct gtggcgattc ccctcaaata ttatcataac 5040
aatttgacag gaacgtttat tttatgcgag gccatggaga aatacggcgt caagaaaatc 5100
gtattcagtt catctgcgac agtatacggc gttccggaaa catcgccgat tacggaagac 5160
tttccattag gcgcgacaaa tccttatggg cagacgaagc tcatgcttga acaaatattg 5220
cgtgatttgc atacagccga caatgagtgg agcgttgccg tgcttcgtta ctttaaccgg 5280
ttcggcgcgc atccaagcgg acggatcggg gaagaccgga acggaatccc aaataacctt 5340
atgccgtatg tggcacagggt agcagtcggg aagctcgagc aattaagcgt attcggaaat 5400
gactatccga caaaaagacgg gacaggcgta cgcgattata ttcacgtcgt tgatctcgca 5460
gaaggccacg tcaaggcgct ggaaaaagta ttgaactcta caggagccga tgcatacaac 5520
cttggaacag gcacaggcta cagcgtgctg gaaatgggtc aagcctttga aaaagtgtca 5580
gggaaagagg ttccataaccg ttttgcggac cgcgctccgg gagacatcgc cacatgcttt 5640
gcagatcctg cgaaagccaa gcgagaacta ggctgggaag cgaaacgcgg ccttgaggaa 5700
atgtgtgctg attcctggag atggcagtct tctaattgtg atgggtataa gagtgccgaa 5760
taagaatgga ggccttctca attgagaagg ccttttttaa agaacaaggg tgcctaaaca 5793
ggcacccttg ttagctgtta tttgattttc acg

```

<210> 4
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer
 B5860H10

<400> 4
 ttacatccgc gggtagaggaa agacaggac

29

<210> 5
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer
 B5860H11

<400> 5
 tagtgaattc agaaccggtc cacatcc

27

<210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>

10028

<223> Description of Artificial Sequence: Primer 181804

<400> 6

tggtcccgag aatggaggcc ttctcaattg

30

<210> 7

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 181805

<400> 7

tggttgatga catctgaggg aggtacaatt gtagctg

37

<210> 8

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 188502

<400> 8

ttttcatcga tactagtgtg cacggatcca tctgaaggtc gatacggg

48

<210> 9

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 188836

<400> 9

ttgtttgtcg acgcaaagct gttttatgaa ttctcc

36

<210> 10

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 190694

<400> 10

ttttggcca gccggccaac aggtcatttt ttaggaggg

39

<210> 11

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequenc : Primer 190695

<400> 11

ttattggatc cgtgaaaatc aaataacagc taacaaggg

39

10028

<210> 12
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 190697

<400> 12
ttttcatcga taacagggtca ttttttagga ggg

33